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ABSTRACT 
The mechanisms by which the pathways regulated by the steroid hormones and the epidermal 
growth factor (EGF) family control mammary development are unclear. We have identified the 
CUB and zona pellucida-like domain containing protein-1 (CUZD1) as a target of estrogen 
regulation in the mouse mammary epithelium. Mice lacking Cuzd1 exhibited a striking 
impairment in steroid-induced proliferation of mammary ductal and alveolar epithelium. Our 
study revealed that Cuzd1 controls the production of a subset of EGF family growth factors, 
neuregulin-1, epigen and epiregulin, which act via the ERBB receptors on the mammary 
epithelial cells. Interestingly, exposure of these cells to the EGF-like growth factors stimulated 
CUZD1 expression, triggered its nuclear translocation, and promoted CUZD1-dependent 
mitogenic activity. We postulated that a regulatory loop, involving the EGF-like growth factors 
and CUZD1, contributes to mammary epithelial proliferation, and that dysregulation of CUZD1 
expression may induce tumorigenesis. Indeed, orthotopic injection of mammary epithelial cells 
overexpressing Cuzd1 into mammary glands of mice led to the development of malignant breast 
tumors, which metastasized to other tissues. Analysis of Cuzd1 expression in primary human 
breast tumors revealed a significantly elevated expression of this gene in tumors displaying a 
high level of estrogen receptor alpha (ESR1) and ERBB signaling.  Collectively, these findings 
suggested that uncontrolled expression of CUZD1, which is a unique integrator of steroid- and 
EGF family-induced growth pathways in normal mammary epithelium, leads to breast 
tumorigenesis. Designing therapeutics that target CUZD1 may offer a novel intervention strategy 
against breast tumor progression, invasion and metastasis.  
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PART A: SIGNALING NETWORKS IN MAMMARY GLAND DEVELOPMENT AND 
TUMORIGENESIS 
Steroid Hormone Regulation of Mammary Gland Development 
The development of the mammary gland is a unique biological process because it is one of the 
very few organ systems where most of the development takes place after birth. There are two 
tissue compartments that constitute the mammary gland: the epithelium composed of ductal 
epithelial cells, myoepithelial cells and milk producing alveolar cells; and the stroma, also 
known as the mammary fat pad. The development of the epithelium in the mammary gland 
occurs in well-defined stages. In a newborn animal, only a small rudimentary ductal tree 
structure, composed of mammary epithelium, is present.  At puberty, this ductal tree undergoes 
accelerated growth and branching induced by pubertal hormones, which eventually lead to the 
formation of an extended ductal system that fills the entire fat pad in a mature virgin mouse. 
These ducts branch into smaller ducts that terminate in lobules composed of alveoli. The second 
phase of development, known as alveologenesis, takes place during pregnancy, leading to the 
formation of the lobuloalveolar tissue. The alveolar cells later differentiate to become milk 
producing cells (Fig1.1) [1, 2] . 
A number of signaling molecules have been implicated in the control of proliferation, 
differentiation, survival and apoptosis of mammary epithelial cells during development. These 
include steroid hormones, such as 17-estradiol (E) and progesterone (P), peptide hormones, 
such as prolactin, growth factors, such as amphiregulin, cell cycle regulators, such as p27 and 
cyclinD1, and transcription factors, such as CEBP or β and LEF1[3]. Specifically, E and the 
EGF-like growth factors stimulate ductal morphogenesis in the pubertal mammary gland. During 
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recurrent estrous cycles in the adulthood, E, P and the EGF family members promote ductal side 
branching. During pregnancy and lactation, these hormones and growth factors act in concert 
with PRL to induce alveologenesis with lactational differentiation [1, 4, 5].  
E acts via estrogen receptor alpha (ESR1) to control mammary epithelial function. The 
Esr1-null mice exhibit severely compromised ductal morphogenesis during puberty and fails to 
execute alveologenesis [6-9]. However, global deletion of Esr1 also leads to the failure of E 
signaling throughout the hypothalamic-pituitary axis, resulting in decreased circulating levels of 
P and PRL that contribute to the severity of the observed phenotype [6]. Recently, a conditional 
deletion mouse model in which Esr1 is selectively ablated in the adult mammary epithelium has 
demonstrated that signaling via this receptor is important for the branching morphogenesis and 
lobuloalveolar differentiation during pregnancy [8]. However, the identities of the downstream 
pathways that mediate critical E-regulated functions during mammary gland development remain 
largely unknown. 
ERBB signaling network during mammary gland development 
Another distinct signaling pathway that is intimately associated with mammary gland 
development is the ERBB (Erythroblastic Leukemia Viral Oncogene-related) signaling network, 
also known as the Epidermal Growth Factor Receptor (EGFR) family. This network comprises 
four homologous receptor tyrosine kinases, named ERBB1-4, that are activated by structurally-
related ligands belonging to the EGF family, including heregulins and neuregulins. All members 
of the ERBB family have in common an extracellular ligand-binding domain, a single 
transmembrane domain and a cytoplasmic domain containing protein tyrosine kinase activity. 
The EGF family ligands bind to the extracellular domain of ERBB receptors, triggering the 
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formation of receptor homo- or heterodimers. This dimerization event stimulates intrinsic 
tyrosine kinase activity of the receptors and promotes autophosphorylation of specific tyrosine 
residues within the cytoplasmic domain. The phosphorylated tyrosines then serve as docking 
sites for cytoplasmic signaling proteins, resulting in the activation of several downstream 
signaling pathways, such as the Ras-MAP kinase cascade, the AKT/PI3 kinase pathway and the 
STAT transcription factors. These signaling events regulate cell proliferation, migration, 
differentiation or survival of mammary epithelial cells [10, 11].  
In the mammary gland, all four ERBBs are expressed at various stages of development of 
this tissue.  While only ERBB1/EGFR and ERBB2 proteins are detected in the developing virgin 
gland, all four ERBB receptors are expressed and activated during pregnancy and lactation [12]. 
Mouse models have provided important insights regarding the roles of the ERBB-signaling 
network in mammary gland development. The first indication for a contribution of ERBB1 to 
mammary gland function came from waved-2 mice, in which the gene encoding ERBB1 is 
mutated. These mice show impaired alveolar development, leading to reduced milk production 
[13]. Subsequent mouse models also supported a potential role for ERBB1 in controlling ductal 
outgrowth [14, 15]. Mice expressing a dominant negative ErbB2 transgene fail to develop a 
functional alveolar compartment during pregnancy, indicating that ErbB2 plays an essential role 
in mammary gland development during pregnancy [16]. Although ERBB3 lacks intrinsic 
tyrosine kinase activity, its heterodimerization with ERBB2 and other ERBB receptors suggests 
a possible role in alveolar development [17]. Finally, conditional deletion of ErbB4 in the 
mammary epithelium resulted in alveolar units that failed to undergo complete functional 
differentiation, indicating a critical role of this receptor in alveolar development [18]. Among the 
EGF family of ligands, amphiregulin (AREG), which acts primarily via ERBB1, is required for 
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mammary ductal elongation in the adolescent mouse, whereas the neuregulins (NRGs) and their 
receptors, ERBB3 and ERBB4, which are predominantly expressed in mammary glands of 
pregnant mice, are critical for alveologenesis [18-21] Collectively, these studies confirmed the 
importance of the ERBB-signaling network during mammary gland development.  
Cross-talk between estrogen and ERBB signaling pathways during normal mammary 
gland development 
There are many reports in the literature indicating a functional link between the ERBB/EGFR 
signaling network and the ESR1 signaling pathway. It was proposed that E acting via ESR1 in 
the stroma induces the production of the EGF ligands, which stimulate proliferation of the 
mammary epithelial cells during puberty. This model was supported by observations that arrest 
of ductal outgrowth and disappearance of TEBs seen in ovariectomized pubertal mice were 
rescued when 17β-estradiol was administered locally by means of slow-release pellets [22]. 
Similarly, pellets releasing EGF, TGF-α, or amphiregulin were also able to induce cell 
proliferation, TEB formation, and ductal elongation [23, 24]. Studies by Brisken and coworkers 
showed that AREG is an essential mediator of Esr1 action in ductal morphogenesis during 
puberty [21]. AREG, however, is not involved in the subsequent development of the mammary 
gland, raising the possibility that other EGF family ligands may mediate epithelial cell 
proliferation at later stages of mammary gland development, such as side-branching and alveolar 
expansion.  
ESR1-mediated signaling in breast cancer  
Many of the signaling networks that control mammary gland growth and differentiation are also 
involved in breast carcinogenesis. Dysregulation of these molecules results in uncontrolled cell 
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proliferation and survival, leading to tumor initiation and progression [25]. Signaling by 
ESR1the ERBB/EGFR network, and the interaction between these two pathways have long 
been implicated in breast carcinogenesis. There is strong evidence to suggest that cumulative 
exposure to E represents a significant determinant of an individual’s lifelong risk of developing 
breast cancer [26]. In fact, ESR1 is expressed in 40-70% of all breast tumors and these tumors 
exhibit E responsive growth. ESR1-mediated signaling controls genes that belong to several 
distinct biological categories, such as cell cycle regulators, modulators of apopotosis, growth 
factors, cytokines, transcription factors and coregulators that drive initiation, progression and 
metastases of breast cancer [27, 28]. For example, SRC-3/AIB1, a coactivator of ESR1, is highly 
amplified in approximately 5% of primary breast cancers, and overexpressed in as many as 60% 
of primary tumors, suggesting a role of E-dependent gene expression events in tumorigenesis 
[29, 30]. Recognition that E is important in mammary tumorigenesis has led to the use of 
tamoxifen, an ESR1 antagonist, and aromatase inhibitors, which block the in vivo production of 
E, in the treatment of ESR1-positive breast cancers [31].  
ERBB/EGF family signaling pathways in breast cancer 
The 30-50% of breast tumors that do not express ESR1 are termed ER-negative and frequently 
overexpress members of the ERBB family. Several lines of evidences suggest that 
overexpression or mutation of ERBB network components, including ERBB1/EGFR, 
ERBB2/Neu, and the EGF family ligands, contributes significantly to initiation of breast cancer 
in humans and rodents [32]. For example, transgenic mice in which the EGF family ligand TGFα 
is overexpressed in the mammary gland developed mammary tumors with high efficiency and 
long latency [33]. Ample evidence has now accumulated, indicating that ERBB2 (HER2/Neu) 
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plays a primary role in many instances of human breast cancer. Numerous studies have 
confirmed that the HER2/Neu gene is amplified and overexpressed in 20-30% of human breast 
tumors [34]. These findings have prompted novel therapeutic strategies targeting HER2/Neu, 
including the monoclonal antibody Herceptin. A gene knock-in approach, introducing 
HER2/Neu sequence with a point mutation in mouse genome, resulted in mice that produced 
mammary tumors with long latency [35]. Molecular analysis also revealed that the HER2/Neu 
locus was amplified between two-and 22- fold in these tumors.  
ERBB3 forms strong heterodimers with ERBB2 and this partnership is important for the 
proliferation of breast cancer cell lines that depend on ERBB2 signaling pathways [17]. In fact, 
parallel overexpression of these proteins has been observed in mammary tumors. The 
significance of ERBB4 in breast cancer remains unclear, given that both oncogenic and tumor 
suppressive roles have been proposed for it [36]. A role for ERBB4 in mammary epithelial cell 
proliferation and its frequent overexpression in early stages of breast cancer have been reported 
previously [37, 38]. Studies proposing its role as a good prognostic marker has also been 
reported [39, 40]. Although the roles of ERBB1 & ERBB2 in breast cancer are well defined, a 
deeper understanding of the actions of ERBB3 & ERBB4 during this disease process is needed. 
Cross-talk between ESR1 and ERBB signaling pathways in breast cancer 
There is increasing evidence that the ESR1- and ERBB-mediated signaling pathways interact 
during tumor proliferation and this may occur via common downstream signaling pathways. It is 
well known that a number of signaling molecules, including MAPK, PI3K, AKT, NFκB, PKCδ 
and PLCγ that control cell proliferation, angiogenesis and invasion during carcinogenesis and 
metastases, also play a role in both ESR1 and ERBB signaling [41]. A number of genes that are 
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involved in cell proliferation and survival in breast cancer, such as cyclin D1, c-myc and Bcl-XL, 
lie downstream of both ESR1 and ERBB pathways, providing clear evidence for the presence of 
nodes of molecular cross talk between the two [42]. The interaction between these two pathways 
is bidirectional and there are several lines of evidence to make this case.  
It is well known that the EGFR/ERBB2-MAPK signaling pathway, in addition to directly 
driving cell growth, can also target and phosphorylate key serine residues within the AF-1 
domain of ESR1 in breast cancer cells. Phosphorylation of these residues, in particular serine-
118, which is a target for extracellular signal-regulated kinases 1/2 (ERK1/2), promotes co-
activator recruitment and activation of ESR1 transcriptional activity [43]. It was also shown that 
E induces the expression of EGF family ligands, such as EGF, amphiregulin and TGF-α and the 
expression of ERBBs, such as EGFR, during proliferation of breast cancer cells [44, 45]. Both 
genomic (nuclear) and non-genomic (membrane and cytoplasmic) ESR1 activities are likely to 
be involved in the cross-talk with the growth factor pathways[46].  
The interaction between ESR1 and the EGF-like growth factor pathways has been 
highlighted as a possible mechanism underlying endocrine resistance in breast cancer. In the 
breast tumors that overexpress ESR1, antiestrogen therapy is effective in inhibiting the tumors. 
However, the breast tumors that overexpress members of the ERBB signaling pathway are 
described as more aggressive and are resistant to endocrine therapies [47, 48]. Strategies to 
disrupt these pathways by using specific inhibitors are clearly necessary to develop effective 
therapeutics to combat endocrine resistance. 
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PART B: CUZD1, A CRITICAL REGULATOR OF NORMAL MAMMARY GLAND 
DEVELOPMENT 
 
Identification of Cuzd1 as a novel E-regulated gene in the mammary epithelium 
Recent studies in our laboratory identified CUZD1, Cub and Zona pellucida-like Domain- 
containing Protein-1 (also known as ERG1 or UO-44) as a critical integrator of the E and ERBB 
signaling pathways during mammary gland development. E regulates the gene encoding CUZD1 
in the mammary gland. Cuzd1 was originally cloned by Kasik and also by our laboratory from 
rodent reproductive tract [49, 50]. This protein was subsequently found to be present in the 
oviduct, ovary, pancreas and epididymis [49, 51-53].  The human CUZD1 gene shares strong 
sequence identity (~80%) with the mouse gene [54]. CUZD1 is a unique protein containing one 
zona-pellucida (ZP) and two tandem CUB motifs both of which have possible roles in cell 
adhesion and cell surface binding [49, 50, 54]. Not much is known about the functional 
significance of these motifs, although their presence is often noted in molecules involved in 
developmental processes [55].  
To examine whether E regulates Cuzd1 expression in the mammary gland, 
ovariectomized mice were treated with or without E. As shown in Fig. 1.2A, administration of E 
to ovariectomized mice stimulated Cuzd1 mRNA expression in both uterine and mammary 
tissues. In contrast, administration of P had no effects on Cuzd1 mRNA levels (data not shown). 
Immunohistochemical (IHC) analysis, using an antibody against mouse Cuzd1, indicated a 
marked increase in the level of CUZD1 protein in the ductal epithelia of the mammary gland 
upon E treatment (Fig. 1.2B, panel b). The expression of CUZD1 in the mammary epithelium 
partially overlapped with that of ESR1 (Fig. 1.2B, panel d). 
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To further investigate whether the E regulation of Cuzd1 expression is mediated by 
ESR1, we utilized HC11 cells, a non-transformed mammary epithelial cell line containing low 
levels of endogenous ESR1. These cells were transduced with adenoviral vectors expressing 
ESR1 or green fluorescence protein (GFP). As shown in Fig 1.2C, overexpression of ESR1 in 
these cells induced a robust time-dependent increase in Cuzd1 mRNA. This induction was 
further enhanced in response to E treatment and strongly inhibited in the presence of ICI 182, 
780, an antagonist of ESR1. Collectively, these in vitro studies supported our in vivo findings 
that E acting via ESR1 stimulates Cuzd1 expression in mammary epithelial cells.  
Cuzd1 controls mammary ductal development and alveologenesis  
To investigate the functional roles of CUZD1 in mammary gland development, we created 
Cuzd1-null mice in which this gene is deleted from mouse germ line by homologous 
recombination using mouse embryonic stem cells. A 6-month breeding study revealed that the 
Cuzd1-null females are fertile and deliver normal size litters. However, ~75% of the delivered 
pups died within 72 h after birth (data not shown) and it was observed that they had insufficient 
milk in their stomachs. Almost all pups survived and grew normally when they were transferred 
to a foster mother immediately after birth. These results indicated that the Cuzd1-null mothers 
fail to produce an adequate amount of milk to nurse their pups.  
To further examine the phenotypic defects, morphological analyses of whole mounts of 
mammary glands were performed at different stages of development. In comparison to their 
heterozygous littermates, the mammary ductal outgrowth was significantly delayed in the 
pubertal glands (6-weeks postnatal) of Cuzd1-null mice (Fig. 1.3, a and b). When examined 
during pregnancy, mammary glands of mutant mice exhibited a severe deficiency in tertiary 
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branching during and impaired alveolar development during pregnancy (Day 18, Fig 1.3, c and 
d) and lactation (Day 2, Fig. 1.3, e and f).  
 
Cuzd1 controls steroid-dependent mammary epithelial proliferation 
The delay in ductal elongation and impaired alveolar development in Cuzd1-null mammary 
glands raised the possibility that CUZD1 is involved in the control of steroid-induced epithelial 
proliferation. To test this possibility, we examined mammary epithelial proliferation in response 
to E and P stimulation.  Cuzd1-null mice and their heterozygous littermates were treated with E 
and P for 5 days to mimic the hormonal effects on alveolar development during early pregnancy. 
Mammary glands were subjected to whole mount and IHC analysis using Ki67 antibody. As 
shown in Fig. 1.4, administration of E and P led to extensive side branching and robust alveolar 
budding in the heterozygous mice (panel a).  The majority of mammary epithelial cells of these 
mice showed positive staining for Ki67 (c and e). In contrast, E and P induced only limited side 
branching, poor alveolar development (panel b) and reduced proliferation rate in mammary 
glands of Cuzd1-null mice (d and f). By our estimation of ki67-positive cells using image J, there 
was a ~70% reduction in cell proliferation activity in the mutant epithelium (panel g). We also 
monitored PGR expression in these tissues by IHC. No significant alteration in the percentage of 
PGR-positive cells was observed in the mammary epithelial cells of these mice, indicating that 
PGR-mediated signaling is unlikely to be affected in the absence of Cuzd1 (Fig.1.4, panels h and 
i). 
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Loss of Cuzd1 impairs the production of a subset of EGF family growth factors in the 
mammary epithelium 
To identify the signaling pathways that operate downstream of Cuzd1, a microarray analysis was 
performed to compare the gene expression profiles of mammary epithelial cells isolated from 
Cuzd1-null mice and their heterozygous littermates on day 18 of pregnancy.  Our results revealed 
that the expression of mRNAs encoding three key members of the EGF family, neuregulin-1 
(Nrg1), epiregulin (Ereg) and epigen (Epgn), are significantly down-regulated in the Cuzd1 (-/-) 
epithelium compared to the Cuzd1 (+/-) epithelium (Fig 1.5A). Interestingly, no significant 
alteration was seen in the expression levels of mRNAs of several other EGF-family growth 
factors, such a amphiregulin (Areg), epidermal growth factor (Egf), heparin binding epidermal 
growth factor (Hbegf), neurgulin-2 (Nrg2), neuregulin-3 (Nrg3) and neuregulin-4 (Nrg4).  
The IHC analyses of NRG1 and EPGN further confirmed that Cuzd1 regulates the 
expression of these proteins in mammary epithelium. Abundant NRG1 or EPGN was detected in 
mammary epithlia of control mice during lactation (Fig. 1.5B, a and b). The expression levels of 
these factors were dramatically diminished in the mammary glands of Cuzd1-null mice (Fig. 
1.5B, c and d). Taken together, these results indicated that Cuzd1 is necessary for the production 
of a specific subset of EGF family ligands, NRG1, EREG and EPGN, which are critical 
mediators of mammary epithelial proliferation and alveologenesis during pregnancy and 
lactation. 
 
Loss of Cuzd1 impairs ERBB signaling pathway 
 
The EGF family ligands signal via ERBB receptors to control mammary gland development [15, 
18-20, 56]. Binding of these ligands to the receptors leads to their activation via auto-
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phosphorylation of critical tyrosine residues, which subsequently serve as docking sites for 
further signaling cascades [11]. We, therefore, examined whether the observed alterations in the 
expression levels of NRG1, EREG and EPGN in the mammary tissue affected the ERBB 
receptor-mediated signaling. Mammary gland sections obtained from mice during late pregnancy 
(day 18) were subjected to IHC, using antibodies directed against specific phospho-tyrosine 
residues critical for activation of ERBB1 (Tyr 1068) ERBB2 (Tyr 877), and ERBB4 (Tyr 1056). 
As shown in Fig. 6A, abundant activating phosphorylation of ERBB1, ERBB4 and ERBB2 was 
observed in mammary epithelia of Cuzd1 (+/-) mice (panels a, c, and e), consistent with the 
considerable proliferative activity seen in this tissue. In contrast, the activating phosphorylation 
of ERBB1 and ERBB4 was markedly reduced in Cuzd1-null epithelium (Fig 1.6A, panels b and 
d). Interestingly, the phosphorylation of ERBB2 was not affected in the mutant epithelium (Fig 
1.6A, panel f). No alteration was observed in the mRNA and protein levels of ERBB1, ERBB2, 
and ERBB4 in mammary epithelia of these mice, indicating that Cuzd1-driven production of a 
specific subset of ligands control corresponding ERBB receptor activation (data not shown). 
It is known that signaling downstream of ERBB4 activates the transcription factors 
STAT5a and STAT5b, which control mammary epithelial cell proliferation and differentiation 
during alveologenesis [57-59]. No significant change in the levels of Stat5a and Stat5b mRNAs 
was observed in the mammary glands of Cuzd1 (+/-) or Cuzd1 (-/-) mice (data not shown). 
STAT5 proteins are activated via phosphorylation of Tyr-694. We, therefore, examined the 
status of STAT5 phosphorylation (Tyr-694) in the mammary glands of pregnant mice by IHC 
analysis. We observed a striking loss of STAT5 phosphorylation in the mammary epithelia of 
Cuzd1-null mice (Fig 1.6B, panel b), whereas abundant phospho-STAT5 was present in the same 
tissue of Cuzd1 (+/-) littermates (Fig.1.6B, panel a).  These results are consistent with the 
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hypothesis that Cuzd1-mediated production of EGF-like growth factors activates ERBB4 
signaling, which is transduced downstream via the activation of STAT5 to control mammary 
epithelial proliferation and differentiation.  
 
In summary, to study the functional role of Cuzd1 in mammary gland development, we 
created Cuzd1-null mice by germ line mutagenesis. Phenotypic analysis of adult mutant females 
revealed a severe impairment in ductal side branching and alveolar development in the mammary 
gland during pregnancy and lactation. Ablation of Cuzd1 resulted in reduced steroid-induced 
mammary epithelial proliferation. This study, using in vivo and in vitro approaches, uncovered 
novel mechanisms linking Cuzd1 to the EGF-like growth factor signaling pathways that guide 
epithelial proliferation and differentiation during key developmental phases of the mammary 
gland. 
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FIGURES 
Fig.1.1
Fig 1.1. Stages of mammary gland development 
Development of mammary gland begins in the fetus (a). A small ductal tree is present in the 
newborn animal (b). Accelerated growth and branching induced by puberty hormones leads to 
the formation of extended ductal sustem that fills the entire fat pad in a mature virgin mouse (c & 
d). Alveolar development occurs during pregnancy (e). The alveolar epithelial compartment is 
eliminated during involution (f).  
This figure is adapted from Henninghausen and Robinson, Dev Cell, 2001 
 
Pregnancy & 
Lactation 
Involution    Adult 
Fetus   Birth  Puberty 
20 
 
 
Fig. 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V 
E 
Cuzd1                       ESR1 
a 
b d 
A. B. 
C. 
c 
21 
 
 
Fig. 1.2.  E regulation of Cuzd1 expression in the mammary gland.  
A. Ovariectomized mice were treated with Vehicle (V) or estradiol (E) at 40 ug/kg body weight 
(E). After 24 h, total RNAs were isolated from whole uteri (UT) and purified epithelial cells 
isolated from mammary gland (MG) and subjected to real-time PCR using gene-specific primers 
for Cuzd1 or 36B4 (control). Quantitative analysis was performed of induction of Cuzd1 mRNA 
expression from three independent experiments after normalization to the level of 36B4 (Mean ± 
SEM). (Courtesy: Quanxi Li). 
B. Localization of CUZD1 and ESR1 in mammary glands in response to E administration. 
Mammary glands of adult mice were collected following 5 days of treatment with vehicle (V) or 
estrogen (E) and paraffin-embedded sections were subjected to IHC analysis using an antibody 
specific for CUZD1 (a and b) or ESR1  (c and d). The reddish brown spots represent 
immunostaining. Magnification, 20X. Inset magnification: 40X (Courtesy: Quanxi Li and Athi 
Kannan).  
C. HC11 cells were transduced with adenovirus expressing ESR1 or green fluorescence protein 
(GFP).  24 h post transduction, cells were treated with vehicle (V), E, or E plus ICI for 24h (grey 
bars) or 48h (black bars). Total RNA was isolated and subjected to real-time PCR using gene 
specific primers for Cuzd1 or 36B4. Relative level of Cuzd1 mRNA at each time point was 
plotted following normalization with respect to the 36B4 mRNA level (Mean ± SEM). 
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Fig.1.3. Reduced ductal branching and impaired alveolar development in Cuzd1-null 
mammary glands. 
Whole mount analysis of no. 4 inguinal mammary glands of virgin heterozygous Cuzd1 (+/-) and 
homozygous Cuzd1 (-/-) mice at 6 weeks (a and b),  pregnancy day 18 (c and d) and lactation day 
2 (e and f). Magnification: 4x. (Courtesy: Quanxi Li). 
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Fig. 1.4. Cuzd1 controls steroid-induced mammary epithelial proliferation.  
No. 4 inguinal mammary glands were collected from Cuzd1 (+/-) and Cuzd1 (-/-) mice following 
5 days of E+P-treatment and subjected to whole mount analysis (a and b). Magnification, 4X. 
Mammary tissue sections from the same mice were subjected to IHC analysis using anti-Ki67 
antibody (panels c, e, d, f) or PGR antibody (panels h and i).  Panels c and d represent a 
mammary duct. Panels e and f represent an alveolar bud. Magnification, 20x. The estimation of 
the number of Ki67-positive cells in Cuzd1 (+/-) and Cuzd1 (-/-) mammary tissue was performed 
using image J. Data (panel g) were expressed as average +/- S.D of three separate measurements. 
(Courtesy: Quanxi Li and Athi Kannan). 
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Fig.1.5. Cuzd1 controls the expression of a subset of EGF family ligands in the mammary 
epithelium.  
A.  Total RNA was isolated from purified mammary epithelial cells of Cuzd1 (-/-) mice and their 
(+/-) littermates at day 18 of pregnancy. Real-time PCR was performed to analyze relative 
expression levels of Epgn, Ereg, Egf, Hbegf, Areg, Btc (Betacellulin), Nrg1, Nrg2, Nrg3 and 
Nrg4. Data are represented as average fold induction ± SEM. Statistically significant differences 
(P<0.05) are indicated by *.  (Courtesy: Quanxi Li).  
B. IHC analysis of Epgn (a and c) and Nrg1 (b and d) protein expression in mammary glands of 
Cuzd1 (+/-) and Cuzd1 (-/-) mice on lactation day 2 (L2). Magnification, 10x 
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Fig. 1.6. Loss of Cuzd1 expression leads to impairment of activation of ERBB1, ERBB4 and 
STAT5 in mammary epithelium during pregnancy  
Mammary tissue sections obtained from Cuzd1 (+/-) and Cuzd1 (-/-) mice on Day18 of 
pregnancy were subjected to IHC using antibodies specific for phospho-ERBB1 (a and b), 
phospho-ERBB2 (c and d), phospho-ERBB4 (e and f), and p-STAT5 (6B, a and b) to assess the 
activation of ERBB-mediated signaling pathways. The immunostaining of phospho-ERBB1, 
phospho-ERBB4, and phospho-STAT5 was sharply diminished in the ductal and alveolar 
epithelium of Cuzd1 (-/-) mice. Magnification, 10X. (Courtesy: Quanxi Li and Athi Kannan). 
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CHAPTER 2 
 
 
 
 
ANALYSIS OF THE ROLE OF CUZD1 IN A MOUSE MODEL OF BREAST 
TUMORIGENESIS 
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ABSTRACT 
 
The role of cellular signaling mediated by the epidermal growth factor receptor (ERBB) family in 
breast tumor growth and progression is well documented. We have recently found that CUZD1, an 
estrogen-regulated protein, critically controls mouse mammary epithelial cell proliferation by 
regulating the expression of a specific subset of epidermal growth factor (EGF)-like growth 
factors in the mammary tissue. Over-expression of Cuzd1 gene in the non-transformed mouse 
mammary epithelial HC11 cells created HC11-Cuzd1 cells, which proliferated at a faster rate than 
the control HC11-LacZ cells. In addition, the HC11-Cuzd1 cells exhibited signs of transformation, 
such as the ability to form colonies on soft agar and increased migration in transwell assays. The 
tumorigenic property of these cells was further assessed by orthotopic injection into the mammary 
glands of adult nude or BALB/c mice. No palpable tumor was observed in mice injected with the 
HC11-LacZ cells. In contrast, animals injected with HC11-Cuzd1 cells invariably developed 
mammary tumors, which progressed to metastasis. Histological evaluation of these tumors 
revealed highly proliferative adenocarcinomas in which active signaling by the ERBB receptors, 
ERBB1 and ERBB4, was observed. Attenuation of expression of ERBB1, ERBB3 and ERBB4 in 
HC11-Cuzd1 cells effectively inhibited CUZD1-promoted cell proliferation, confirming a critical 
functional link between CUZD1 and the ERBB pathway. Interestingly, treatment of HC11 cells 
with the EGF-like growth factors stimulated Cuzd1 expression, triggered the nuclear translocation 
of CUZD1 protein, and promoted CUZD1-dependent mitogenic activity. We postulated that a 
regulatory loop, involving Cuzd1 and the EGF-like growth factors, contributes to normal 
mammary epithelial proliferation. Abnormal elevation in Cuzd1 expression triggers uncontrolled 
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cell proliferation and tumorigenesis. Collectively, these results indicated that Cuzd1, by enhancing 
the signaling output of the ERBB pathways, plays a critical role in breast tumorigenesis. 
INTRODUCTION  
 
Breast tumorigenesis often arises from the overexpression of signaling molecules otherwise 
involved in normal cellular processes of growth, development, and differentiation [1]. Disruption 
of signaling pathways regulated by the estrogen receptor alpha (ESR1) and ERBB growth factor 
receptors, which are essential for normal mammary gland development and lactation, results in 
uncontrolled epithelial cell proliferation, leading to mammary tumorigenesis [2].  
Overexpression of the ERBB family of ligands and receptor tyrosine kinases is frequently 
observed in breast cancer and correlates with poor patient prognosis and therapeutic resistance. 
For example, in a transgenic mouse model in which the EGF family ligand, TGFα, is 
overexpressed in the mammary gland, the animals developed mammary tumors with high 
efficiency [3]. Ample evidence has now accumulated, indicating that ERBB2 (also known as 
HER2/Neu) plays a primary role in many instances of human breast cancer. Numerous studies 
have confirmed that the ERBB2 gene is amplified and overexpressed in 20-30% of human breast 
tumors [4] These findings have prompted novel therapeutic strategies targeting ERBB2, 
employing the monoclonal antibody Herceptin.  ERBB3 forms strong heterodimers with ERBB2 
and this partnership is important for the proliferation of breast cancer cell lines that depend on 
ERBB2 signaling pathways [5]. In fact, parallel overexpression of these proteins has been 
observed in mammary tumors. The significance of ERBB4 in breast cancer remains unclear, 
given that both oncogenic and tumor suppressive roles have been proposed for it [6]. A role for 
ERBB4 in mammary epithelial cell proliferation and its frequent overexpression in early stages 
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of breast cancer have been reported previously [7, 8]. Studies, proposing that it is a good 
prognostic marker, have also been reported [9]. Aberrant activation of the ERBBs has often been 
implicated in resistance to targeted chemotherapeutics in breast cancer. Various strategies have 
been explored to target the ERBB network [10] , including antibodies and gene therapy; however 
the potential for exploiting this pathway is still in its infancy. A more thorough understanding of 
the mechanisms that regulate the expression of ERBBs and their ligands is necessary in order to 
design effective therapeutic strategies that will interfere with their function. 
There is increasing evidence that signaling pathways downstream of ESR1 and ERBB 
interact during tumor proliferation. It is well known that a number of signaling molecules, 
including MAPK, PI3K, AKT, NFκB, PKCδ and PLCγ, which control cell proliferation, 
angiogenesis and invasion during carcinogenesis and metastases, are activated downstream of 
both ESR1 and ERBB signaling [11]. Similarly, a number of genes that are involved in cell 
proliferation and survival in breast cancer, such as cyclin D1, c-myc and Bcl-XL, lie downstream 
of both ESR1 and ERBB pathways, providing evidence for the presence of nodes of molecular 
cross-talk between the two [12]. However, the precise mechanisms that mediate the cross-talk 
between the ESR1 and ERBB pathways are largely unknown. 
Our recent studies revealed that CUZD1, a previously reported estrogen regulated gene 
(17), is required for mammary epithelial proliferation and differentiation. CUZD1 also regulates 
the induction of a subset of EGF family mitogenic factors that act via the ERBB signaling system 
to promote epithelial proliferation and differentiation during mammary gland development and 
lactation (Chapter 1). It is our hypothesis that CUZD1 acts as an integrator of the steroid 
hormone and EGF signaling pathways to regulate mammary gland development.   
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Since many molecules that belong to the proliferative and morphogenic program of 
mammary gland development are often altered or harnessed to support aberrant growth and 
tumorigenesis, we considered the possibility that dysregulation of CUZD1 expression may lead 
to uncontrolled cell proliferation and contribute to cancer initiation or progression. Previously 
published work has shown that Cuzd1 is overexpressed in many ovarian cell lines and tumors, 
suggesting that it might have a role in ovarian tumorigenesis [13].  
In this study, we demonstrate that overexpression of CUZD1 in untransformed mammary 
epithelial cells stimulates cell proliferation, cell transformation and eventually leads to 
development of mammary adenocarcinoma. Using mouse breast tumor tissue, we also establish a 
critical link between CUZD1 and ERBB signaling pathways during the initiation and progression 
of breast tumorigenesis.  
 
MATERIALS AND METHODS 
 
Cell line and cell culture 
The HC11 cells (generous gift from Dr. Mrinalini Rao of UIC) are a non-transformed mammary 
epithelial cell line derived from midpregnant BALB/C mice.  These cells were grown in RPMI 
1640 (Invitrogen) supplemented with 5% (v/v) fetal bovine serum (Hyclone), 10 ng/ml EGF 
(Sigma) and 5 ug/ml insulin (Sigma).  
 
Creation of Cuzd1 overexpression cell lines  
cDNA encoding Cuzd1 was cloned into the lentiviral vector plenti6.3/V5 TOPO (Invitrogen). 
The plenti6.3-Cuzd1 and a control plasmid containing the LacZ gene were transfected into 
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293FT along with the lentivirus packaging mixture (according to manufacturer’s instructions) to 
produce lentiviral particles. HC11 cells were then transduced with Cuzd1 or control lentiviral 
particles and selected using blasticidin (Invitrogen) to create a stable cell line overexpressing 
LacZ or CUZD1.  
 
 
RNA isolation and real-time PCR analysis 
Total RNA was extracted from cultured HC11 cells using Trizol RNA purification kit 
(Invitrogen) according to manufacturer’s instructions. Reverse transcription was performed using 
the cDNA synthesis kit (Stratagene) following manufacturer’s instructions. cDNA was amplified 
by quantitative real-time PCR analysis using gene-specific primers and SYBR-Green supermix 
(Bio-Rad Laboratories). 36B4 was used as the loading control. For a given sample, threshold 
cycle (Ct) and SD was calculated from individual Ct values from 3-4 replicates of a sample. 
Normalized mean Ct was computed as ΔCt by substracting mean Ct of 36B4 from Ct of a target 
gene for control sample. ΔΔCt was then calculated as a difference in ΔCt values between control 
and experimental groups. The fold change in gene expression was then computed as 2
-ΔΔCt
. Error 
bars indicates
 
2
-ΔΔCt
  ± SD.  
 
Cell proliferation using BrdU incorporation 
HC11-LacZ or -Cuzd1 cells were plated at a density of 5x10
3
 cells/well in 96-well plates and
 
cultured for 24 h in full growth medium. After 24 h, cells were washed twice with PBS and 
incubated in serum-starvation
 
medium (RPMI with no FBS) for 48 h. Medium was replaced with
 
RPMI with 10% FBS or with starvation medium (control) and incubated with 
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Bromodeoxyuridine (BrdU) (100 µM) for 24 h. The uptake of BrdU was quantified using 
ELISA-based cell proliferation
 
assay according to the manufacturer’s instructions (Roche).  
 
siRNA-mediated transient transfection 
HC11 cells were transfected with siRNA against Cuzd1 or control siRNA (scrambled), using 
Lipofectamine-RNAimax reagent following the manufacturer’s protocol (Invitrogen, CA). 
Briefly, lipofectamine was mixed with 50 nM of siRNA, and allowed to form siRNA-liposome 
complexes, which were then added to HC11 cells at 60% confluency. After 24 h, the transfection 
was repeated again. Cells were harvested 48 h after the second transfection and total RNA was 
isolated and analyzed by quantitative real-time PCR using gene-specific primers.  
Anchorage-independent growth in soft agar 
HC11-Lacz or -Cuzd1 cells (1 × 10
4
) or MCF7 cells (control) were seeded in six-well plates with 
a bottom layer of 0.48% Bacto agar in DMEM and a top layer of 0.36% Bacto agar in DMEM. 
Fresh DMEM containing 10% FBS was added to the top layer of the soft agar. The culture 
medium was changed twice a week. After 16 d, colonies were stained with 0.005% crystal violet. 
Visible colonies (>0.5 mm in diameter) were counted from representative views from triplicate 
experiments and the average number of colonies per well was determined. 
 
Boyden chamber cell migration assay 
Boyden-chambers (Millipore) were placed in 24-well dishes containing chemoattract media 
(RPMI containing 10% FBS).  Serum-starved HC11-LacZ or -Cuzd1 cells (1 x 10
5
 cells/well) 
were added to the upper compartment and allowed to incubate for 72h at 37°C. Cells that 
migrated across into the lower chamber of the membrane were quantified by CyQuant 
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(Millipore) flurometric assay according to the manufacturer’s instructions. Means were taken 
from three individual chambers for each experiment. 
 
Orthotopic injection of cells into mammary gland 
HC11-LacZ or -Cuzd1 cells (1 × 10
6
) were suspended in Matrigel and injected into the teat of the 
fourth abdominal mammary gland of nude (nu/nu) mice as described [14]. Tumor growth was 
measured by weekly caliper measurement for a period of 18 weeks. All animal experiments were 
conducted in accordance with a protocol approved by University of Illinois Institutional Animal 
Care and Use Committee. After 18 weeks, the mice were euthanized by CO2. The primary 
mammary tumors, superficial lymph nodes, lungs and livers were harvested from sacrificed 
animals and fixed in 4% paraformaldehyde for subsequent H&E staining or 
immunohistochemistry 
 
Histology, immunohistochemistry & immunofluroscence  
Organs were fixed in 4% paraformaldehyde overnight, paraffin embedded, and cut into 4- to 5-
μm sections. After high-temperature antigen retrieval in citrate or EDTA buffer, sections were 
stained with H&E. Immunohistochemistry was done on parallel sections overnight at 4°C, with 
primary antibodies directed against CUZD1 (in-house), PCNA (Santa Cruz Biotechnology), 
EPGN (R&D systems), NRG1 (Abcam), phospho-EGFR (Y1068, Cell Signaling), phospho-
ERBB2 (Y877, Cell Signaling), ERBB3 (Santa Cruz Biotechnology), phospho-ERBB4 (Y1056, 
Santa Cruz Biotechnology), phospho-ERK1/2 or phospho-AKT1/2/3 (Santa Cruz 
Biotechnology). Bound primary antibodies were detected with horseradish peroxidase (HRP)–
35 
 
conjugated goat anti-mouse or goat anti-rabbit secondary antibodies (Jackson Laboratiories). 
Sections were counterstained with hematoxylin and mounted.  
For immunofluroscence-based translocation experiments, HC11 cells were serum starved 
for 48h and followed by treatment with vehicle (citrate buffer) or Epigen (20ng/ml) or Nrg1 
(50ng/ml) (Peprotech, CA). After 24h treatment, the cells were fixed in 3.7% formaldehyde, 
permeabilized, blocked and incubated overnight with primary antibody against Cuzd1 (in-house).  
Subsequently, slides were washed in PBS with 0.1% Triton-X and incubated with Alexa Flour 
488-conjugated anti-rabbit IgG. Slides were stained for DAPI and mounted.  
 
 
 
 
 
 
RESULTS 
 
 
Cuzd1 overexpression increases rate of proliferation of HC11 cells  
 
To assess the functional role of CUZD1 in mammary epithelial proliferation, we stably 
overexpressed Cuzd1 in HC11 cells, a non-transformed mouse mammary epithelial cell line 
derived from Balb/c mice in mid-pregnancy. Control HC11 cells, overexpressing LacZ, were 
also generated. We noted that the HC11-Cuzd1 cells expressed markedly higher levels of 
CUZD1 mRNA and protein compared to the HC11-LacZ cells (Fig 2.1A), confirming that we 
have successfully created a mammary epithelial cell line overexpressing Cuzd1.  
We next compared the rates of proliferation of HC11-Cuzd1 and HC11-LacZ cells, using 
a quantitative BrdU incorporation assay. We observed that the HC11-Cuzd1 cells exhibited 
significantly higher rates of proliferation relative to the HC11-LacZ cells (Fig 2.1B). Consistent 
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with this observation, the HC11-Cuzd1 cells exhibited markedly elevated expression of several 
factors that play critical regulatory functions in the cell cycle progression. For example, the 
HC11-Cuzd1 cells expressed elevated levels of several factors that promote G1-S phase 
transition, such as cyclins A1 and B1, Cdk1 and Cdk4, E2F1, and reduced levels of p27, a Cdk-
inhibitor (Fig 2.1C). Taken together, these results confirmed that Cuzd1 expression positively 
regulates proliferation of mammary epithelial cells.  
Cuzd1 promotes expression of a subset of EGF family ligands and their ERBB receptors in 
HC11 cells 
Previous studies in the mouse (Chapter 1) indicated that a subset of the EGF family of ligands is 
down regulated and the activation of ERBB1 and ERBB4 is impaired in the mammary epithelia 
of the Cuzd1-null mice. Consistent with these previous results, assessment of the expression of 
the EGF family ligands and their receptors in the Cuzd1-overexpressing HC11 cells showed that 
Cuzd1 specifically stimulates the expression of epigen (EPGN), epiregulin (EREG) and 
neuregulin-1 (NRG-1) without altering the expression levels of the other EGF family members 
(Fig 2.2). It is important to note that the expression of the ERBB receptors, ERBB1, ERBB3 and 
ERBB4, was also elevated in HC11-Cuzd1 cells compared to the control HC11-LacZ cells. 
Cuzd1, therefore, not only controls the expression of the EGF ligands, but also that of key ERBB 
receptors, thereby driving the increased rate of proliferation seen in HC11-Cuzd1 cells.  
ERBB signaling is critical for the proliferation of HC11-Cuzd1 cells 
To further evaluate the role of the ERBBs in the control of Cuzd1-mediated cell proliferation, we 
used siRNA targeted to the mRNAs corresponding to ERBB 1-4. The expression of each of the 
ERBB mRNAs in HC11-Cuzd1 cells was attenuated and the impact of this intervention on cell 
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proliferation was measured. Attenuation of mRNA levels of ERBB1 or ERBB3 or ERBB4 led to 
a marked reduction (50-60%) in cell proliferation, whereas suppression of ERBB2 mRNA did 
not exert any significant effect (Fig 2.3, A and B). These results confirmed a functional link 
between ERBB signaling and Cuzd1-mediated cell proliferation. 
 
 
The EGF family ligands control expression and nuclear translocation of the CUZD1 
protein 
In the mouse mammary epithelial cells in vivo, the CUZD1 protein is present in both nucleus and 
cytoplasm (Chapter 1, Fig 1.1B). When the HC11 cells were grown in a medium without serum, 
CUZD1 showed mostly cytosolic localization. Interestingly, addition of medium containing 
serum triggered nuclear localization of this protein (data not shown). We next tested whether 
EGF-like factors in the serum could promote nuclear translocation of CUZD1. As shown in Fig 
2.4, panels B and C, upon stimulation with EPGN or NRG1, CUZD1 was localized in the 
nucleus. Additionally, treatment of HC11 cells with EPGN or NRG1 markedly up-regulated 
Cuzd1 mRNA levels (Fig 2.4A). Collectively, these results raised the possibility that 
overexpression of Cuzd1 may create an autocrine positive feedback signaling loop in which 
CUZD1 up-regulates the expression of EPGN, EREG, and NRG1, and their ERBB receptors; the 
activated ERBB signaling pathway then promotes Cuzd1 expression, triggers the nuclear 
translocation of CUZD1 protein, which, via an unknown mechanism contributes to stimulated 
production of these EGF-like growth factors. We postulate that establishment of such an 
autoregulatory signaling loop may contribute to uncontrolled Cuzd1-driven mammary epithelial 
cell proliferation, leading to breast cancer. 
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Overexpression of Cuzd1 leads to transformation of HC11 cells  
To test whether the overexpression of Cuzd1 promotes tumorigenic transformation of mammary 
epithelial cells, we performed the soft agar assay to assess anchorage independent growth, a 
well-known marker of cell transformation. Whereas the HC11-Cuzd1 cells formed large colonies 
when cultured in media containing soft agar, the HC11-LacZ cells remained as single cells in the 
agar suspension. As a control, we used MCF7 breast cancer cells, which are known to form 
robust colonies on soft agar (Fig 2.5A). When subjected to a cell invasion assay in which cells 
are tested for their ability to migrate across a barrier, the HC11-Cuzd1 cells exhibited 
significantly higher motility than the control HC11-LacZ cells. We used MDAMB-231 breast 
cancer cells, which are highly migratory and metastatic, as a positive control in this experiment  
(Fig 2.5B). Additionally, HC11-Cuzd1 cells expressed elevated levels of the metalloproteases 
MMP2 and MMP9 (Fig 2.5C), both of which have been heavily implicated in breast tumor 
invasion and metastasis [15, 16]. Our findings indicate that the overexpression of Cuzd1 in HC11 
cells induces two important hallmarks of tumor-like transformation in these cells, the ability to 
form colonies and exhibit increased migratory properties.  
HC11-Cuzd1 cells form breast tumors in mice 
 
We next investigated whether the HC11-Cuzd1 cells form breast tumors in vivo. To test this 
possibility, we orthotopically injected HC11-lacZ or HC11-Cuzd1 cells into the teats of the 
mammary glands of nude mice. The injected cells penetrated into the ducts and lodged 
themselves in the fat pad. In mice injected with HC11-Cuzd1 cells, palpable breast tumors were 
detected as early as two weeks post-injection. Tumors did not appear in mice injected with 
HC11-lacZ cells. The tumor growth in mice injected with HC11-Cuzd1 cells was assessed 
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weekly, using digital calipers, and compared to mice injected with HC11-LacZ cells. The breast 
tumors continued to grow over the eighteen weeks assessment period, reaching sizes between 
200-250 mm
2
 (Fig 2.6 A and B). This growth pattern was observed in 100% of the mice that 
were injected with HC11-Cuzd1 cells compared to none in mice injected with HC11-LacZ cells. 
Mice were sacrificed eighteen weeks following injection and tumors were removed and 
examined by H&E staining. The tumors were verified as high-grade adenocarcinomas upon 
pathological examination (Fig 2.7A, bottom panels). Upon immunohistological assessment of the 
tumor tissue, we observed a robust expression of CUZD1 in both cytoplasmic and nuclear 
compartments (Fig 2.7B, left panel). These tumors also expressed a high level of PCNA, 
indicative of proliferative activity (Fig 2.7B, right panel). Therefore, the overexpression of 
Cuzd1 in mammary epithelial cells led to the formation of high-grade mammary 
adenocarcinomas, establishing it as a novel tumor-promoting gene in breast cancer.  
We also performed similar experiments, using Balb/c mice, the strain of mice from which 
HC11 cells are derived. Injection of the HC11-Cuzd1 cells into mammary glands of these mice 
also led to the formation of breast tumors, although at a relatively slower pace (data not shown).  
Activation of ERBB signaling in Cuzd1-driven tumorigenesis  
 
We next investigated, using IHC, the expression levels of selected EGF family ligands and the 
ERBB receptors in CUZD1-overexpressing breast tumors. The expression of high levels of 
EPGN and NRG1 was evident in the tumor sections (Fig. 2.8, panels a and b). Abundant active 
forms of ERBB1, ERBB3 and ERBB4 (panels c, d, f) were also present in the tumor tissue. In 
contrast, activated ERBB2 was undetectable in the tumor (panel e). These results were in 
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agreement with our previous finding that overexpression of Cuzd1 involves active signaling by 
ERBBs 1, 3 and 4, but is not accompanied by ERBB2 activation.  
Activation of ERBB receptors is often accompanied by activation of downstream ERK1/2 and/or 
PI3K-AKT pathways. To assess ERK1/2 and PI3K-AKT activation in Cuzd1-overexpressing 
tumors, IHC was performed, using antibodies against phospho-ERK1/2 or phospho-AKT1/2/3 
(panels g and h). Our results showed the presence of abundant phospho-ERK1/2, but not 
phospho-AKT in the tumor tissue, indicating that the activation of downstream ERK1/2 
signaling is the predominant mechanism by which CUZD1 regulates proliferation of breast 
tumor cells.  
 
DISCUSSION 
 
Creation of the Cuzd1-null mouse model in our laboratory had previously allowed us to defined 
the critical role of this gene in epithelial cell proliferation during mammary gland development 
(Chapter 1). Our studies indicated that the ERBB signaling network is activated downstream of 
Cuzd1. The present study provided direct evidence that elevated expression of Cuzd1 stimulated 
the production of a subset of EGF family ligands and their ERBB receptors. These included 
EPGN, EREG and NRG1, which act via ERBBs 1, 3 and 4. Attenuation of these ERBB receptors 
in Cuzd1-overexpressing cells inhibited cell proliferation, thereby revealing the critical 
importance of ERBB signaling in Cuzd1-mediated cell proliferation. Interestingly, ERBB2, 
whose activation is frequently associated with breast cancer, does not appear to mediate the 
effects of Cuzd1. Collectively, our results suggested that the mitogenic activity downstream of 
41 
 
Cuzd1 is mediated via activation of the ERBB signaling system, presumably via formation of 
homo- or heterodimers between ERBB1, ERBB 3 and ERBB 4. 
Ample evidence in the literature suggests that activation of the ERBB pathway plays a key role 
in generating and maintaining malignant phenotypes, including cell proliferation, differentiation, 
invasion and tumor cell survival [17]. This raised the possibility that constitutive Cuzd1-driven 
activation of the ERBB signaling network may lead to breast tumorigenesis. The present study 
provides direct evidence for the tumorigenic potential of Cuzd1. Overexpression of this gene in a 
non-tumorigenic mammary epithelial cell line resulted in rapid cell proliferation and anchorage 
independent growth, hallmarks of premalignant phenotypes of mammary epithelial cells. The 
Cuzd1-overexpressing cells formed tumors in vivo. When injected orthotopically into mammary 
glands of nude mice, these cells progressed with high frequency, to high-grade mammary 
adenocarcinomas. It is important to note that the same response was also noted in normal Balb/c 
mice, albeit at a slower rate, indicating that it is not a phenotype that occurs only in 
immunocompromised mice. These results established the role of Cuzd1 as a critical player in 
breast tumorigenesis.  
The growth of breast cancer cells is controlled by cellular growth factors that stimulate 
proliferation, migration and differentiation of the tumor cell. A variety of growth factors, such as 
insulin-like growth factors, transforming growth factor α, fibroblast growth factors and EGF 
family growth factors, are known to stimulate the proliferation of breast cancer cells [18, 19]. In 
cell culture studies, we have shown that treatment with EPGN or NRG1 robustly stimulates the 
expression of Cuzd1 in HC11 cells.  In addition, exposure of HC11 cells to these EGF-like 
growth factors triggers nuclear translocation of CUZD1. Our studies suggested a critical nuclear 
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role of CUZD1, which promotes the synthesis of EPGN, EREG and NRG1. Interestingly, Cuzd1 
itself does not possess a nuclear localization signal. So, its nuclear translocation and mechanism 
of action are likely dependent on interactions with as yet unknown nuclear proteins. Perhaps its 
translocation to the nucleus occurs in association with a transcription factor, which then 
participates in the regulation of the growth factor genes. Future biochemical experiments will 
explore the mechanisms by which Cuzd1 achieves this regulation. 
              In our proposed model (Fig 2.9), E induces the expression of Cuzd1 in normal 
mammary epithelial cells. The EGF family growth factors, such as EPGN and NRG1, trigger the 
translocation of the CUZD1 protein to the nucleus. CUZD1 then act in the nucleus to control the 
production of EPGN, EREG and NRG1 and their ERBB receptors via an unknown mechanism. 
Secretion of these growth factors leads to enhanced activation of the ERBB and ERK1/2 
signaling pathway, promoting mammary epithelial cell proliferation. These results suggest that 
constitutive overexpression of Cuzd1 may result in the establishment of an autoregulatory loop 
that drives uncontrolled epithelial cell proliferation and tumorigenesis. Our findings, therefore, 
provide a plausible mechanism by which elevated levels of Cuzd1 give rise to high-grade 
mammary adenocarcinomas. 
Invasion by malignant cells requires degradation of the extracellular matrix (ECM) and 
the basement membrane. Cuzd1-overexpressing cells showed invasive properties as assessed by 
the transwell migration assays. Indeed, in mice bearing tumors larger than 150mm
2
, the primary 
tumors metastasized to distant sites. Metastatic lesions were observed in the liver and lung (data 
not shown).  It is plausible that Cuzd1 may be involved in reprogramming cancer cells toward a 
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potentially more invasive state, leading to invasion and metastases. The potential role of Cuzd1 
role in metastasis is currently under investigation in our laboratory.  
 
In summary, we have identified Cuzd1 as a critical regulator of breast tumorigenesis. Our 
finding supports the concept that Cuzd1, which controls the proliferative program of mammary 
gland development, when dysregulated, promote the genesis of breast cancer. Designing 
therapeutics that target Cuzd1 may offer a novel intervention strategy for ERBB-dependent 
breast cancers.   
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FIGURES 
Fig. 2.1 
A.  
 
 
 
 
 
 
 
 
B.  
 
 
 
 
 
C.  
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Fig 2.1. Overexpression of Cuzd1 leads to an enhanced rate of HC11 cell proliferation. 
A. HC11 cells were transduced with lentivirus harboring Cuzd1 or LacZ cDNA to create stable 
cells overexpressing Cuzd1 (HC11-Cuzd1) or LacZ (HC11-LacZ), respectively.   Total RNA was 
isolated from these cells and subjected to real-time PCR using Cuzd1-specific primers to validate 
Cuzd1 mRNA expression.  
B. HC11-Cuzd1 and HC11-LacZ cells were cultured under serum-free condition for 48 h and 
then medium containing 10% FBS was added. BrdU was administered 24 h prior to cell harvest, 
and BrdU incorporation was measured using an ELISA-based assay. The relative levels of BrdU 
incorporation from three independent measurements are shown (Mean ± SEM).  
C. HC11-LacZ and HC11-Cuzd1 were serum-starved for 48 h and stimulated with FBS for 24 h. 
RNA was prepared from these cells and subjected to real-time PCR analysis using gene-specific 
primers to assess  the expression of E2F Transcription-1 (E2F1), p27, Cyclin dependent kinase 
1& 2 (Cdk1 &2), Cyclin A1 and Cyclin B1  
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Fig. 2.2 
 
 
 
 
 
 
Fig. 2.2. Cuzd1 regulates the expression of a subset of EGF family ligands and ERBB 
receptors in HC11 cells 
HC11-Cuzd1 and HC11-LacZ cells were cultured for 48 h in serum-free media and then exposed 
to 10% FBS for 24 h. RNA was isolated and real-time PCR was performed to analyze relative 
expression levels of Epgn, Ereg, Egf, Hbegf, Areg, Btc, Nrg1, Nrg2, Nrg3 and Nrg4. Data are 
represented as average fold induction ± SEM.  
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Fig. 2.3 
A.  
 
 
 
 
 
B. 
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Fig. 2.3. Regulation of proliferation of HC11-Cuzd1 cells by ERBB receptors 
A. HC11-Cuzd1 cells were transfected with siRNA (50nM each) targeted against ERBB1-4 
or scrambled siRNA (control) as described in the Materials and Methods. Total RNA was 
prepared from these cells 48 h post-transfection and subjected to real-time PCR analysis, 
using gene-specific primers, to assess the expression of ERBB 1-4 mRNAs.  
B. HC11-Cuzd1 cells were transfected with siRNA to attenuate the expression of ERBB1-4. 
48 h post transfection, the siRNA transfection mixture was removed and replaced with fresh 
growth medium. BrdU was added at this point and its incorporation was measured after 24 h, 
using an ELISA-based BrdU assay, according to the manufacturer’s protocol. 
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Fig. 2.4 
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Fig. 2.4. Regulation of Cuzd1 expression and translocation of CUZD1 protein in response to 
the EGF family ligands 
A. HC11 cells were serum starved for 48 h followed by treatment with epigen (20 ng/ml) or 
neuregulin-1 (50 ng/ml) for 24 h. Control cells were treated with vehicle. RNA was 
isolated from all treatment groups and subjected to quantitative real-time PCR, using 
gene-specific primers for Cuzd1. 
B. HC11 cells were serum starved for 48 h and stimulated with epigen (20 ng/ml) for 24 h. 
Cells were fixed and subjected to immunofluroscence, using an antibody specific for 
CUZD1. Positive staining for CUZD1 is indicated in green and DAPI stained nuclei are 
shown in blue. 
C. HC11 cells were serum starved for 48 h and stimulated with neuregulin-1 (50ng/ml) for 
24 h. Cells were fixed and subjected to immunofluroscence, using an antibody specific 
for CUZD1. Positive staining for CUZD1 is indicated in green and DAPI stained nuclei 
are shown in blue. 
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Fig. 2.5 
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Fig. 2.5 (cont.) 
C. 
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Fig 2.5. Overexpression of Cuzd1 leads to transformation of HC11 cells  
A. MCF7 cells (control) or HC11-Lacz or HC11-Cuzd1 cells were plated in media containing 
soft agar. Colonies were allowed to form for 16 days and stained with crystal violet overnight. 
Visible colonies (>0.5mm) were counted, using a dissecting microscope. Data are presented as 
mean+/- standard error from three independent experiments. Figures below show a representative 
colony from each treatment group.  
B.  Serum-starved MDAMB-231 cells (positive-control) or HC11-LacZ or HC11-Cuzd1 cells 
were placed in Boyden chambers and allowed to migrate toward 10% FBS for 72 h. The number 
of invading cells was quantitated, using CyQuant fluroscence labeling (grey bars), and compared 
to corresponding cells without exposure to the serum (black bars). Data are presented as mean+/- 
standard error from three independent experiments 
C. HC11-LacZ and HC11-Cuzd1 were serum-starved for 48 h and stimulated with FBS for 24 h. 
RNA was prepared from these cells and subjected to real-time PCR analysis using gene-specific 
primers to assess  the expression of MMP2 and MMP9 (Matrix-degrading metalloprotease)  
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Fig. 2.6 
A.  
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Fig. 2.6.  HC11 cells overexpressing Cuzd1 form tumors in vivo 
 
A. HC11-LacZ or HC11-Cuzd1 cells were injected orthotopically into the teat of the 4th 
mammary gland of immunocompromised female nude mice. Mice were sacrificed 18 
weeks post injection and examined for tumor growth. Top panels represent an exterior 
view of the animal and bottom panels show the mammary gland after dissection. 
B. Tumor volume was quantified weekly using digital calipers from time of injection (week 
0) to time of sacrifice (week 18). Tumor volume=1/2(length × width
2
)  
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Fig. 2.7 
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Fig 2.7.  HC11 cells overexpressing Cuzd1 form high-grade mammary adenocarcinomas  
 
A. Mammary glands (HC11-LacZ, top panel) or tumors (HC11-Cuzd1, bottom panel) were 
collected 18 weeks post-injection, fixed, embedded in paraffin, sectioned and subjected to H&E 
staining. Left panels are 5x images and right panels are 40x images. 
B. Mammary tumor tissue of mice injected with HC11-Cuzd1 cells were collected, fixed, and 
embedded in paraffin. Serial sections of these tissues were subjected to IHC analysis, using 
antibodies against CUZD1, pan-cytokeratin and PCNA. Figures are 40x images.  
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Fig.2.8  
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Fig. 2.8. Tumors resulting from HC11-Cuzd1 cells express high levels of EGF-like ligands 
and ERBB receptors 
 
Mammary tumor tissue from mice injected with HC11-Cuzd1 cells were collected, fixed, and 
embedded in paraffin. Serial sections of these tissues were subjected to IHC analysis, using 
antibodies against epigen (a), neuregulin-1 (b), phospho-ERBB1/EGFR (c), ERBB3 (d), 
phospho-ERBB2 (e), phospho-ERBB4 (f), phospho-ERK1/2 (g) or phospho-AKT (h). 
Magnification: 40X. Inset in (e) show ductal cells within the sample that stain positive for p-
ErbB2 
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Fig. 2.9  
 
 
Fig 2.9. Propsed model for Cuzd1-mediated breast tumorigenesis 
 
E induces the expression of Cuzd1 in normal mammary epithelial cells. The EGF family growth 
factors, such as EPGN and NRG1, trigger the translocation of the CUZD1 protein to the nucleus. 
CUZD1 then act in the nucleus to control the production of EPGN, EREG and NRG1 and their 
ERBB receptors via an unknown mechanism. Secretion of these growth factors leads to 
enhanced activation of the ERBB and ERK1/2 signaling pathway, promoting mammary 
epithelial cell proliferation. These results suggest that constitutive overexpression of Cuzd1 may 
result in the establishment of an autoregulatory loop that drives uncontrolled epithelial cell 
proliferation and tumorigenesis  
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CHAPTER 3 
 
 
 
THE ROLE IN CUZD1 IN HUMAN BREAST CANCER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
ABSTRACT 
 
Our laboratory has recently identified Cuzd1 as a novel estrogen (E)-regulated gene in the mouse 
mammary gland. Deletion of the Cuzd1 gene from the mouse genome resulted in greatly reduced 
proliferation of the mammary epithelium in response to E and progesterone (P), indicating a 
central role of this gene in steroid-induced growth of the mammary gland. The Cuzd1 gene is 
highly conserved between the mouse and the humans. The linkage between Cuzd1 and mammary 
epithelial proliferation raised the possibility that it might be involved in the uncontrolled 
proliferation of human breast cancer cells. Screening of several breast cancer cell lines for Cuzd1 
expression revealed that Cuzd1 is present in low or undetectable levels in ESR1-negative tumor 
cells lines, but is expressed at high levels in ESR1-positive cell lines. Small interfering RNA 
(siRNA)-mediated attenuation of Cuzd1 expression in human breast carcinoma MCF7 cells led 
to a dramatic loss of E-induced proliferation of these cells. This observation hinted at an 
important connection between Cuzd1 and E-dependent breast cancer. The siRNA-mediated 
downregulation of Cuzd1 also significantly reduced the expression levels of epigen (EPGN) and 
epiregulin (EREG), growth factors belonging to the EGF family, indicating that Cuzd1 regulates 
the ERBB signaling in human breast cancer cells. Analysis of Cuzd1 expression in primary 
human breast tumors revealed a significantly elevated expression of this gene in tumors 
displaying a high level of ESR1 and ERBB signaling, compared to normal (control) breast 
tissues. Collectively, these studies indicated that Cuzd1 regulates uncontrolled proliferation of 
human breast cancer cells by acting as a critical integrator of the ESR1 and ERBB signaling 
pathways. 
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INTRODUCTION 
 
An extensive body of basic and clinical research established that the steroid hormone estrogen 
(E), acting via its receptor ESR1, controls epithelial proliferation during normal mammary gland 
development as well as uncontrolled cell division in hormone-dependent breast malignancies. 
Although ESR1 is expressed in 40-70% of breast cancers, the exact mechanism by which E 
controls tumorigenesis is unknown. To understand this, it is necessary to identify E-regulated 
molecular pathways that mediate the proliferative actions of E in the breast tissue [1-5]. 
Although ample evidence has accumulated, implicating the epidermal growth factor (EGF) 
signaling pathway as a downstream mediator of E-induced growth of human breast tumors, the 
precise molecular mechanisms that connect these signaling pathways during mammary gland 
development or carcinogenesis remain unclear [6-10]. Understanding the key players which 
integrate the E & ERBB signaling pathways to regulate
 
the proliferation of breast cancer cells is 
critical to the development
 
of novel targeted therapies for cancer prevention and treatment. 
We have identified Cuzd1 as a novel E-regulated gene in the mouse mammary gland. The 
mammary tissue of Cuzd1-null mice exhibits significantly delayed ductal outgrowth during 
puberty. A severe impairment in ductal side branching and alveolar development was also 
evident in these mutant mice during pregnancy and lactation. Strikingly, loss of Cuzd1 resulted 
in greatly reduced proliferation of the mammary epithelium in response to E and P, indicating a 
central role of this factor in steroid-induced growth of this tissue. Gene expression profiling 
studies, using wild type and mutant mammary epithelia, further revealed that Cuzd1 critically 
regulates the ERBB signaling pathway during mammary gland development. Collectively, these 
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studies uncovered Cuzd1 gene product as a potential integrator of the growth promoting effects 
of steroid hormone and ERBB receptor pathways during normal mammary epithelial 
proliferation. 
The identification of Cuzd1 as a regulator of E-dependent epithelial cell proliferation 
during normal mammary gland development and its potential significance in breast 
tumorigenesis led us to investigate its role in human breast cancer cells. Like mouse Cuzd1, its 
human ortholog (CUZD1) contains two ZP domains and one CUB domain. The CUB-domain 
containing proteins are developmentally regulated and have known roles in protein adhesion or 
interaction with the extracellular matrices. ZP domains function as conserved modules for 
polymerization of extracellular proteins and are also responsible for sperm-adhesion of the ZP. 
The human CUZD1 shares ~80% identity with the mouse Cuzd1 at the nucleotide level. Cuzd1 
has been implicated in diverse physiological functions, including E-induced proliferation of 
uterine epithelium during early pregnancy [11, 12], protection against severity of pancreatitis 
[13] and cell adhesion [14]. A recent study [14] reported a high level of expression of Cuzd1 in 
human ovarian tumor cells, suggesting a potential role for Cuzd1 in the development of ovarian 
cancers. These findings raised the possibility that Cuzd1 may also play an important role in 
human breast tumorigenesis.  
To study the role of CUZD1 in E-mediated breast tumor cell proliferation, we chose the 
human breast carcinoma cell line, MCF7. These cells express endogenous CUZD1 mRNA and 
CUZD1 protein, and high levels of ESR1. Addition of E to these cells led to a marked 
enhancement in CUZD1 expression. Also, ICI 182,780, a well-known ESR1 antagonist, 
dramatically reduced the expression of CUZD1 in MCF7 cells, indicating that this factor is 
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regulated by ESR1 and a potential downstream mediator of ESR1 function in human breast 
cancer cells. Silencing of CUZD1, using small interfering RNAs (siRNAs), resulted in the 
inhibition of cell growth and proliferation, suggesting a vital role of this gene in E-dependent 
breast cancer cell proliferation. Most importantly, analysis of CUZD1 expression in human 
primary breast tumors revealed elevated expression of its mRNA in ~60% of tumors compared to 
their normal counterparts. There was also a tight correlation between the expression of CUZD1, 
ESR1 and active ERBB1 proteins in primary breast tumors. Our recent breast tumor tissue 
microarray analysis revealed strong correlation between the expression of CUZD1, ESR1 and 
later stages of breast cancer. Taken together, these findings support a potential role for CUZD1 
in human breast tumorigenesis.   
 
MATERIALS AND METHODS 
Cell line and cell culture 
The human non-transformed mammary epithelial cell line, MCF10A and human breast cancer 
cell lines MDAMB468, MDAMB231, BT20, SKBR3, T47D and MCF7 were obtained from 
American Type Culture Collection (ATCC) and cultured according to the manufacturer's 
specifications.  
 
RNA isolation and real-time PCR analysis 
Total RNA was extracted from cultured MCF7 cells using the Trizol RNA purification kit 
(Invitrogen) according to the manufacturer’s instructions. Reverse transcription was performed 
using the cDNA synthesis kit (Stratagene) following manufacturer’s instructions. cDNA was 
amplified by quantitative real-time PCR analysis using gene-specific primers and SYBR-Green 
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supermix (Bio-Rad Laboratories). 36B4 was used as the loading control. For a given sample, 
threshold cycle (Ct) and SD was calculated from individual Ct values from 3-4 replicates of a 
sample. Normalized mean Ct was computed as ΔCt by substracting mean Ct of 36B4 from Ct of 
a target gene for control sample. ΔΔCt was then calculated as a difference in ΔCt values between 
control and experimental groups. Fold change in gene expression was then computed as 2
-ΔΔCt
. 
Error bars indicates
 
2
-ΔΔCt
  ± SD. 
 
For scanning expression levels in human primary tumors, a real-time PCR–based 
TissueScan Breast Cancer Panel containing 48 tissues covering four disease stages and normal 
tissues (Origene) was used to evaluate CUZD1 expression levels in human breast cancers. All 
data were normalized to the endogenous β-actin. 
 
siRNA- mediated transient transfection 
MCF7 cells were transfected with siRNA against CUZD1 or control siRNA (luciferase) using 
Silentfect lipid reagent following the manufacturer’s protocol (Bio-Rad Laboratories). Briefly, 
silentfect was mixed with 150 nM of siRNA, allowed to form siRNA-liposome complexes and 
added to MCF7 cells at 60% confluency. After 24 h, the transfection was repeated again. Cells 
were harvested 48h after the second transfection and total RNA was isolated and examined by 
quantitative real-time PCR using gene-specific primers.  
 
Cell proliferation using BrdU incorporation 
MCF7 cells were plated at a density of 5 x 10
3
 cells/well in 96-well plates and
 
cultured for 24 h 
in full growth medium. Following siRNA transfecion, siRNA was replaced with medium 
containing E (10
-7
 M) and cells were allowed to grow for 72 h. BrdU was added at this point and 
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its incorporation was measured after 24 h using an ELISA-based BrdU assay and the resulting 
color reaction was measured using a plate reader at 370nm. To assess the mitogenic effects of 
epigen, MCF7 cells were grown in media containing low (0.5%) serum and were treated with 
recombinant epigen (20ng/ml). In parallel experiments, positive controls were performed by 
adding EGF (100ng/ml) or E (10
-7
 M) to these cells. BrdU incorporation was measured over a 
period of 24 h. 
 
Immunofluroscence and immunohistochemistry 
MCF10A or MCF7 cells were cultured in media containing 10% FBS for 24 h. Cells were fixed 
in 3.7% formaldehyde, permeabilized, blocked and incubated overnight with primary antibody 
against CUZD1 (in-house).  Subsequently, slides were washed in PBS with 0.1% Triton-X and 
incubated with Cy3-conjugated anti-rabbit IgG. Slides were stained for DAPI and mounted.  
Paraffin-embedded tumor tissue sections from Normal/Stage 0, stage II or IV, that were 
pathologist verified were obtained from Origene. Immunohistochemistry was performed on 
adjacent sections overnight at 4
0
C, with primary antibodies directed against CUZD1 (in-house), 
ESR1 (Novacastra), phospho-EGFR (Y1068, Cell Signaling) or phospho-ERBB4/HER4 (Y1056, 
Santa Cruz Biotechnology). Bound primary antibodies were detected with horseradish 
peroxidase (HRP)–conjugated goat anti-rabbit or anti-mouse secondary antibody (Jackson 
Laboratories). Sections were counterstained with hematoxylin and mounted.  
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Tissue microarray analysis 
A tissue microaaray (TMA), assembled from paraffin-embedded breast cancer tissue samples, 
was provided by the Breast Center of Baylor College of Medicine, Houston, TX. The TMA 
consisted of six slides, each containing 45 breast cancer samples and one internal control sample. 
Information regarding age, disease stage, receptor status for ESR1, PGR and HER2, were 
provided with each slide of the TMA. To perform the CUZD1 expression analysis, slides were 
subjected to IHC using an antibody specific for CUZD1. The images were captured with a 
brightfield microscope within 72 h of staining and were obtained at the following 
magnifications:  5x, 10x, and 20x. The images were scored for positive or negative 
immunostaining by two independent observers.   
 
We assessed the localization and intensity of CUZD1 immunostaining. Cytoplasmic 
staining of CUZD1 was evaluated qualitatively (negative, weak, medium, medium-high and 
strong), while nuclear staining was evaluated quantitatively. Nuclear staining was assessed using 
ImageJ software and the positive cells ranged between negative, weak (<5%), medium (5-10%), 
and high intensities (>10%). Samples with score of medium or higher were considered for the 
analysis. Finally, the CUZD1 expression data were combined with other information regarding 
the tumors to assess correlations with tumor stage and receptor status.   
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RESULTS 
 
E acting via ESR1 regulates CUZD1 expression in MCF7 cells 
  
To investigate the regulation of CUZD1 by E in human breast cancer cells, we added E to 
cultures of MCF7 cells grown in the absence of hormone and monitored the expression of 
CUZD1 and pS2, a well known E-regulated gene, at different time points after ligand addition. 
Upon E treatment, we observed a marked up-regulation of CUZD1 and pS2 (positive control) 
mRNAs at 2 h. The level of pS2 mRNA increased progressively at 10 h and 24 h. On the other 
hand, CUZD1 mRNA level increased robustly at 10 h and then declined at 24 h (Fig. 3.1A). 
When ICI 182,780, an ESR1-antagonist, was added together with E, a drastic reduction in the 
expression of both genes was seen (Fig. 3.1B). These results provided clear evidence that E 
regulates CUZD1 expression in mammary cells in an ESR1-dependent manner.  
 
High levels of CUZD1 mRNA is present in ESR1-positive human breast cancer cell lines 
 
To further investigate CUZD1 expression in breast cancer, we examined 6 human breast cancer 
cell lines (three ESR1-negative and three ESR1-positive) to profile the expression of CUZD1 
mRNA. We observed low or undetectable levels of CUZD1 in ESR1-negative tumor cells lines, 
but significantly higher, from 5-20 fold in ESR1-positive cell lines when compared to non-
transformed MCF10A cells. The expression was highest in MCF7 cells where ESR1 is 
abundantly expressed (Fig 3.1C). Furthermore, localization of CUZD1 protein via 
immunofluroscence revealed a high level of expression in nuclei of MCF7 cells, while it was 
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undetectable in non-transformed MCF10A cells (Fig 3.1D). Taken together, these results 
demonstrated that overexpression of CUZD1 mRNA is correlated with ESR1 expression in 
breast cancer cells.  
 
Attenuation of CUZD1 expression suppresses E-dependent proliferation of MCF7 cells 
 
To confirm the functional role of CUZD1 in E-mediated proliferation of breast cancer cells, we 
employed siRNA strategy to suppress CUZD1 mRNA expression in MCF7 cells. As shown in 
Fig 3.2A, we observed that 48 h following transfection, there was ~80% reduction in CUZD1 
mRNA levels. Transfection of luciferase siRNA had no appreciable effect on CUZD1 mRNA 
levels. In order to determine the role of CUZD1 in E-mediated proliferation of MCF7 cells, an 
ELISA-based colorimetric assay was employed to quantitate the amount of BrdU incorporation 
in cells in which CUZD1 expression was attenuated by siRNAs. In this experiment, 48 h 
following CUZD1 or luciferase (control) siRNA transfection, cells were treated with medium 
containing E for 72 h. The BrdU was then added and its incorporation was assessed after 24 h. 
This experiment showed that E-induced BrdU incorporation was reduced approximately 60% in 
cells treated with CUZD1 siRNA compared to those treated with control siRNA (Fig 3.2B). 
These results provided convincing evidence that CUZD1 is an important regulator of E-mediated 
proliferation of breast cancer cells.  
CUZD1 mediates the expression and mitogenic effects of EPGN & EREG during E-induced 
proliferation of MCF7 cells 
Loss of epigen and epiregulin expression in the mammary epithelia of Cuzd1-null mice indicated 
that these growth factors are regulated downstream of Cuzd1. To determine whether E regulates 
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the expression of these growth factors in MCF7 cells, E was added to cells grown in the absence 
of hormone and the expression of various EGF family of growth factors, such as epigen, 
epiregulin, EGF and amphiregulin, was monitored at different times after E addition. Upon E 
treatment, a marked up-regulation of expression of epigen was observed. The expression of 
epiregulin and EGF was also up regulated by E, although to a lesser extent (Fig 3.3A). The E 
regulation of amphiregulin is well established, [16] hence it was used as a positive control 
Interestingly, attenuation of CUZD1 mRNA expression led to the downregulation of epigen and 
epigregulin, but not EGF, amphiregulin and other EGF-like ligands (Fig 3.3B). These results 
indicated that although E stimulates the production of various EGF family growth factors, the 
induction of only a subset of these factors is mediated by CUZD1.   
It is possible that the EGF family growth factors produced by MCF-7 cells in response to 
E treatment contribute to cell proliferation. To test this possibility, we examined whether epigen 
exerts mitogenic effects on MCF7 cells. For this purpose, an ELISA-based BrdU incorporation 
assay was performed. Treatment with epigen resulted in a three-fold increase in BrdU 
incorporation compared to vehicle-treated control cells. Interestingly, the extent of epigen-
induced cell proliferation was comparable to that induced by EGF or E (Fig 3.3C). Collectively, 
these results supported the hypothesis that E-induced production of a subset of the EGF family 
growth factors, such as epigen, is mediated by CUZD1 and these growth factors play a key role 
in E-dependent proliferation of human breast cancer cells.   
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Elevated expression of CUZD1 in human primary breast tumors 
To further explore the functional link between CUZD1, ESR1 and the EGFR signaling pathway 
during breast cancer, we analyzed the expression patterns of CUZD1, ESR1, ERBB1 and ERBB4 
in primary breast tumors, using real-time PCR based analysis (Fig 3.4A-D). We analyzed the 
expression of these genes in 5 normal breast tissues as well as 43 primary breast tumors obtained 
from patients at different stages of breast cancer ranging from stages I to IV. We observed low 
levels of expression of CUZD1 mRNA in several normal breast tissues that we analyzed. Of the 
primary tumors analyzed, in ~60% of the primary tumors, CUZD1 mRNA expression was 
significantly elevated (at least 6-fold or higher) compared to the normal breast tissue (Fig 3.4A). 
The expression pattern of ESR1 mRNA revealed that ~70% of CUZD1-positive tumors are also 
ESR1-positive (6-fold or higher) (Fig 3.4B). These tumors were also verified as ESR1-positive 
based on the immunohistochemical data provided with the samples. A significant population of 
these tumors was positive for ERBB1 or ERBB4 (2.5-fold or higher) (Fig 3.4 C and D). 
Statistical analysis (Chi-squared test) reveals significant correlation between the expression of 
CUZD1, ESR1 and HER1/HER4 in these cancer samples (P < 0.005) (Fig 4E). Strikingly, 
highest levels of mRNA expression was observed in breast tumors classified as stages III & IV in 
which CUZD1 expression was increased ranging from 10- to 60-fold compared to normal breast 
tissue (Fig 3.4A). This result hints at a link between the expression level of CUZD1 and 
progression of human breast tumorigenesis. 
We next employed IHC to analyze the expression of CUZD1, ESR1, ERBB1 and ERBB4 
proteins in nonmalignant and malignant mammary tissues. We detected low levels of these 
proteins in normal tissues. Consistent with the RNA data presented in Fig. 3.4, significantly 
higher and mostly nuclear expression of CUZD1 protein was observed in Stage III tumor tissue. 
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The nuclear expression of CUZD1 was further increased in the Stage IV/metastatic tissue (Fig 
3.4F). The Stage III tumor tissue sections also exhibited high levels of ESR1, ERBB1 and 
ERBB4 compared to normal/stage 0. Additional Stage IV samples could not be obtained to 
perform the ErbB staining profile. These results again supported a strong correlation between 
CUZD1, ESR1 and the EGFR signaling system in a specific subset of tumors.  
 
CUZD1 expression analysis using human primary breast tissue microarray 
In order to assess the relationship between CUZD1 and tumor stage or receptor status, archival 
breast cancer tissue microarrays (TMA) consisting of 276 individual tumor samples, provided by 
Baylor College of Medicine (BCM), were screened for CUZD1 expression by IHC staining. The 
majority of the tumor samples were ductal carcinomas and information regarding the stage and 
receptor status was available for each individual sample.  For cytoplasmic staining of CUZD1, 
the staining intensity was graded as negative, weak, medium, medium-high and strong. For 
nuclear staining, the percentage of CUZD1-positive cells were determined by image-J software 
and was graded as negative, weak, medium and high. Samples that scored medium or higher 
were considered for the analysis. Representative images for each of these categories are provided 
in Fig 3.5A. Samples in negative or low expression categories were not included in our analysis.  
 
In this study, our first aim was to we investigate whether there is any correlation between the 
overall level of CUZD1 expression, the stage of cancer and its nuclear/cytoplasmic localization. 
Our study revealed that 63% of all samples were CUZD1-positive. CUZD1 was predominantly 
present in the late stages of cancer (IIB, III & IV) as compared to the early stages (0, I and IIA), 
i.e., 61% of all CUZD1-positive tumors were late stage and this observation was statistically 
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significant as determined by the chi-squared test (<0.05) (Fig 5B (i)). There was an 
approximately even split between the cytoplasmic and nuclear localization of CUZD1 in tumor 
samples and no clear correlation emerged between the cellular localization of CUZD1 and tumor 
stage.  
The second goal of this study was to determine whether CUZD1 levels were linked to a specific 
steroid receptor profile of the tumor tissue.  Our analysis revealed that 55% of CUZD1-positive 
tumors were also categorized as ESR1-positive, PGR-positive and ERBB2-negative (++-) and 
this observation was statistically significant as determined by the chi-squared test (<0.05) (Fig 
3.5B (ii)). Interestingly, a small but significant fraction of CUZD1-positive tumors were ESR1-
negative, PGR-negative and ERBB2-negative (---). In conclusion, CUZD1 expression is 
predominantly associated with late stage breast cancers that are positive for ESR1 and PGR but 
negative for ERBB2.  
 
 
DISCUSSION  
 
Abnormal expression of ESR1 is found in many human breast cancers, and about 50% of ESR1-
positive breast cancer patients respond to anti-estrogen therapy [5, 10]. However, the exact 
signaling mechanism by which E controls mammary tumorigenesis remains elusive. To 
understand this, it is necessary to identify E-regulated molecular pathways that mediate the 
proliferative actions of E in the breast tissue. In this study, we have identified CUZD1 as a novel 
E-regulated gene in a human breast cancer MCF7 cells. Addition of ICI 182,780, a pure 
antagonist of ESR1, completely abolished the expression of CUZD1, indicating that its 
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expression is mediated by ESR1.  Furthermore, we demonstrated that the endogenous levels of 
CUZD1 mRNA in a variety of breast cancer cell lines were correlated with their ESR1 status. 
Taken together, these results provide evidence consistent with the ESR1 regulation of CUZD1. 
The induction of CUZD1 as early as 2 h in response to E indicates that it might be a direct, 
primary target gene of ESR1. Recent in silico analysis revealed several potential ESR1 binding 
sites within the 10 kilobase 5’-flanking sequence of the CUZD1 gene (J. Mapes, unpublished 
data). Chromatin immunoprecipitation experiments are underway to determine whether one or 
more of these sites interact with ESR1.  
The proliferative response of MCF7 cells to E is well documented. It was previously 
reported that E induces the expression of several EGF family ligands, such as EGF, AREG and 
TGFα. E also regulates the expression of ERBBs, such as ERBB1, which are known mediators 
of proliferation of breast cancer cells [6, 9]. Recent studies in our laboratory, using the Cuzd1-
null mouse model and mouse model of tumorigenesis (described in Chapters I and II), showed 
that CUZD1 acts by modulating the ERBB signaling pathway, a critical regulator of mammary 
epithelial cell proliferation during normal development and tumorigenesis. Here, we investigated 
whether a similar molecular link exists between CUZD1 and the ERBB signaling pathway in 
human breast cancer cells. Indeed, attenuation of CUZD1 by administration of siRNA targeting 
its mRNA led to a marked reduction in the production of the EGF family growth factors, EPGN 
and EREG, which act via the ERBB signaling pathway. We have demonstrated that Epgn mRNA 
expression is robustly induced by E in MCF7 cells. EPGN also stimulates the proliferation of 
MCF7 cells when added to cell cultures maintained in the absence of serum. In one study, Finak 
et al have reported significant correlation between the expression patterns of CUZD1 and Epgn 
in certain breast tumors (18). Taken together, these results raised the possibility that the 
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mitogenic effect of E in human breast cancer cells is mediated at least in part by CUZD1 via 
production of growth factors, such as EPGN.  
Analysis of human primary breast tumors show that ~60% of these tumors displayed 
significantly up-regulated levels of CUZD1 compared to normal breast tissue. The CUZD1 
mRNA overexpression is also tightly linked to the expression of mRNAs corresponding to ESR1, 
ERBB1 and ERBB4. Since CUZD1 acts as functional link between the ESR1 and ERBB 
signaling pathways, it emerges as a target of therapeutic drugs in the context of a subset of breast 
tumors. 
Our study also suggested a link between CUZD1 overexpression and advanced stages of 
breast cancer. Tissue microarray analysis of over 250 samples revealed significant correlation 
between CUZD1-positive samples and advanced stages of breast cancer. This analysis also 
showed a tight correlation between CUZD1 and tumors that belong to the subtype ESR1-
positive, PGR-positive and ERBB2-negative. Analysis of the Oncomine database, a publicly 
available database summarizing gene expression profiling across tumor tissue types, provided 
additional evidence for a possible relationship between CUZD1 and ESR1 in the context of 
ERBB2-negative breast tumors (15). In one study, statistically significant (p=2.90E-4) up-
regulation of CUZD1 expression was observed in invasive ductal breast carcinoma compared to 
their normal counterparts (17). This and other studies show significant correlation between the 
expression patterns of CUZD1 and ESR1 and inverse correlation between CUZD1 and ERBB2 
expression. Recent studies have shown that the classical adjuvant therapies are not effective for 
ESR1-positive, ERBB2-negative tumors because they often develop endocrine resistance [19]. 
Endocrine resistance is often attributed to the cross-talk between ESR1 and the ERBB pathways 
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[20]. Our study raises the possibility that specific therapeutic drugs targeting CUZD1 may 
prevent endocrine resistance in the ESR1-plus/ERBB2-minus subtype of breast tumors. 
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FIGURES 
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Fig 3.1. Estrogen regulation of CUZD1 in MCF7 breast cancer cells 
A. MCF7 cells grown in E-free culture medium were treated with E (10-8M) for indicated 
times. Cells were harvested at various time points, total RNA was isolated from these cells, and 
subjected to real-time PCR analysis, using gene-specific primers, to assess the expression the 
expression of pS2 (control) and CUZD1.  
B. MCF-7 cells were treated with E in the absence or presence of ICI 182,780 (10-6 M) for 
24 h. Total RNA was isolated and subjected to real-time PCR analysis, using gene-specific 
primers, to assess the expression the expression of pS2 (control) and CUZD1.  
C. Total RNA was isolated from a non-tumorigenic human mammary epithelial cell line, 
MCF10A (control) or breast cancer cell lines MDAMB 468, MDAMB 231, SKBR3 (ESR1-
negative), BT20, T47D, MCF7 (ESR1-positive) and subjected to real-time PCR analysis using 
gene-specific primers to assess the expression of CUZD1. MCF10A was used as the control cell 
line. 
D. MCF10A or MCF7 cells were cultured in 10% FBS for 24 h. Cells were fixed and 
subjected to immunofluroscence using an antibody specific for CUZD1 (orange) and the nuclei 
were stained with DAPI (blue)  
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Fig. 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2. CUZD1 mediates E-regulated proliferation in MCF7 cells  
A. MCF7 cells were transfected with siRNA (150 nm) targeted against CUZD1 or 
Luciferase siRNA (control) as described in the Materials and Methods. Total RNA was prepared 
from MCF7 cells at 48 h after transfection and subjected to real-time PCR, using gene-specific 
primers, to assess the expression of CUZD1. 
B. MCF7 cells grown in E-free culture medium were transfected with 150 nM siRNA 
targeted to CUZD1 or control luciferase mRNA for 48 h. The siRNA was replaced with medium 
containing E (10
-7
 M) and cells were allowed to grow for 72 h. BrdU was added at this point and 
its incorporation was measured after 24 h using an ELISA-based BrdU assay, according to the 
manufacturer’s protocol. 
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Fig.3.3  
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Fig 3.3. CUZD1 mediates the expression and mitogenic effects of EPGN and EREG during 
E-induced proliferation of MCF7 cells 
A. MCF-7 cells grown in E-free culture medium were treated with E (10
-8
M) for indicated times. 
Cells were harvested at various time points, total RNA was isolated from these cells, and 
subjected to real-time PCR analysis, using gene-specific primers, to assess the expression of 
Epgn, Ereg, Egf and Areg mRNA. 
B. MCF7 cells grown in E-free culture medium were transfected with 150 nM CUZD1 or control 
luciferase siRNA for 48 h. Total RNA was prepared from HC11 cells 48 h after transfection and 
subjected to real-time PCR, using gene-specific primers, to analyze relative expression level of 
CUZD1 and Epgn, Ereg, Egf, Hbegf, Areg, Btc, and Nrg1-4. 
C. MCF7 cells grown in E-free culture medium were treated with E (10
-7
 M) or recombinant 
EPGN (20 nM) or EGF (20 nM) for 72 h. BrdU was then added and its incorporation was 
measured after 24 h, using an ELISA-based BrdU assay, according to the manufacturer’s 
protocol. 
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Fig. 3.4 
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Fig. 3.4 (cont.) 
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Fig. 3.4 (cont.) 
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Fig. 3.4. Correlation between Cuzd1, ESR1, ERBB1 and ERBB4 in human primary 
breast tumors  
A-D. A breast cancer TissueScan Real-Time qPCR array, containing five normal/Stage 0                
cDNAs and forty-three human breast cancer cDNAs, was analyzed for expression of CUZD1 
(6A), ESR1 (6B), ERBB1/HER1 (6C) or ERBB4/HER4 (6D) by real-time PCR. Averages of 
relative CUZD1 mRNA expression from two independent plates are plotted with clinical status 
indicated. 
E. The breast cancer tissue samples were categorized based on their CUZD1 status. Relative 
mRNA fold induction of 6 or higher was considered positive. The CUZD1-positive samples 
were then further categorized based on the status of ESR1 and ERBB/HER (ERBB1/HER1 or 
ERBB4/HER4). Relative mRNA fold induction of 6 or higher was considered positive for 
ESR1 and a fold induction of 2.5 fold or higher was considered positive for ERBB1/HER1 and 
ERBB4/HER4.  
F. Tissue sections from normal/Stage 0 and Stage III breast cancer were subjected IHC      
analysis using antibodies against CUZD1, ESR1, ERBB1/HER1 and ERBB4/HER4. Stage IV 
sample was subjected IHC analysis using antibodies against CUZD1 and ESR1. 
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Fig. 3.5 
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Fig 3.5.  Correlation between CUZD1 expression, steroid receptor status and stages of 
breast cancer in human breast tumor tissue microarrays 
A. Representative immunohistochemical images of the nuclear and cytoplasmic scoring of 
CUZD1 staining are shown.  
B. The breast cancer tissue samples were categorized based on their CUZD1 status. For 
cytoplasmic staining of CUZD1, the staining intensity was graded as negative, weak, medium, 
medium-high and strong. For nuclear staining, the percentage of CUZD1-positive cells were 
determined by image-J software and was graded with a score of negative, weak (<5%), medium 
(5-10%), and high intensities (>10%). Samples that were scored medium or higher were 
considered for the analysis. The correlation between CUZD1 and stage of breast cancer is shown 
in upper panel (i). Stages O, I and IA are early stage breast cancers, IIB, III and IV are late 
stages. The correlation between Cuzd1 and receptor status is shown in lower panel (ii). Receptor 
status is represented as ESR1 status, PGR status, ERBB2/HER2 status as determined by IHC or 
FISH by pathologists at Baylor College of Medicine.  
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CHAPTER 4: ON-GOING STUDIES 
 
ROLE OF CUZD1 IN EPITHELIAL MESENCHYMAL TRANSITION (EMT) AND 
METASTASES 
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ABSTRACT 
Our recent studies indicated that overexpression of Cuzd1, a unique integrator of steroid 
hormone- and EGF family-induced growth pathways, in untransformed HC11 mammary 
epithelial cells leads to breast tumorigenesis. Interestingly, immunohistochemical analysis of 
primary mammary tumors derived from HC11-Cuzd1 revealed that 20-30% of the tumor cell 
mass is not epithelial in nature. This cell population resembles mesenchymal cells and may 
represent cells that have undergone epithelial-mesenchymal transition (EMT), which is a critical 
event in the progression toward cancer metastasis. Indeed, in mice bearing tumors larger than 
150 mm
2
, metastatic lesions were observed in the liver and lung. Analysis of expression of well-
known EMT markers in the primary tumor tissue showed a strong up-regulation of the 
mesenchymal-marker vimentin and the transcriptional regulator Snail1. We also observed a 
marked downregulation of the epithelial marker E-cadherin in the primary tumors. To further 
analyze the role of Cuzd1 in EMT and metastasis, we subjected the primary tumors to enzymatic 
digestion and derived cell lines from HC11-Cuzd1 tumors. These cell lines are important tools to 
understand how the gene expression pattern progressively changes from untransformed HC11 
cells to transformed HC11-Cuzd1 cells isolated from the mammary tumor. A preliminary 
microarray analysis was performed comparing the mRNA expression profiles in these cells. This 
analysis revealed a progressive up-regulation of several factors that influence cellular movement, 
invasion, and metastases, particularly the ILK, Rho, TGFβ, and Wnt signaling pathways, and 
downregulation of factors that mediate cell-cell tight junctions. These results are providing an 
initial glimpse of the molecular pathways that are regulated by Cuzd1 during tumorigenesis and 
metastasis. 
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INTRODUCTION  
During breast cancer progression, epithelial cells detach from the primary tumor, and adhere to 
and invade the surrounding stroma. They intravasate into blood vessels and disseminate to 
distant tissues and organs where they extravasate and initiate secondary tumors or metastasis. 
Metastasis underlies the majority of cancer-related deaths [1]. Therefore, understanding the 
molecular mechanisms that enable tumor cell dissemination is a vital health issue. The 
transdifferentiation of epithelial cells to mesenchymal cells, called epithelial-mesenchymal 
transition (EMT), endows tumor cells with enhanced motility and survival attributes that 
facilitate dissemination to permissive niches [2]. Epithelial cells establish close contacts with 
their neighbors through the rearrangement of adherens junctions, desmosomes, and tight 
junctions. Conversely, mesenchymal or stromal cells are loosely organized in a three-
dimensional extracellular matrix and comprise connective tissues adjacent to epithelia. The 
EMT is fundamental for embryonic development and tumor invasion. It involves profound 
phenotypic changes that include the loss of cell-cell adhesion, the loss of cell polarity, breakage 
of tight junctions, degradation of the basement membrane ECM components and the acquisition 
of migratory and invasive properties [3].  
One of the earliest steps in EMT is the loss of E-cadherin function, and in fact it is 
generally accepted that EMT-inducing factors initiate epithelial reorganization by suppressing 
the expression or impairing the function of E-cadherin [4]. Many different extracellular cues 
have been shown to trigger epithelial dedifferentiation and EMT, such as those involving 
transforming growth factor-β (TGF-β), Notch, fibroblast growth factors (FGFs) and Wnt 
signalling pathways [5]. Most of these EMT-inducing signals exert their action through the 
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modulation of transcription factors that (i) repress epithelial genes, such as those encoding E-
cadherin and cytokeratins, and (ii) activate transcription programs that specify fibroblast-like 
motility and an invasive phenotype. Several transcription factors are known to drive EMT, 
including the basic helix loop helix (bHLH) families of transcription factors, and other factors 
such as Twist, Zeb2 (ZEB2/SIP1), and the Snail/Slug family transcription factors [6]. This 
multistep process results in the loss of apical-basal cell polarity and the acquisition of spindle-
shaped morphology, and the gain in expression of mesenchymal-specific genes, such as vimentin 
and N-cadherin [7]. During tumor progression, these changes are thought to promote tumor cell 
migration across the basement membrane and invasion into the surrounding microenvironment, 
ultimately leading to metastasis.  
Although CUZD1 is expressed in the epithelial cells of mammary glands, uterus and 
ovary, its expression in mesenchymal or stromal cells has not been reported. We have shown that 
overexpression of CUZD1 in mouse mammary epithelial cells bestows distinct tumorigenic 
properties on these cells. Most notably, CUZD1-overexpressing cells show invasive properties as 
assessed by the transwell migration assays and also express robustly elevated levels of the 
matrix-degrading metalloproteases, that are known to promote tumor cell motility, invasiveness, 
and EMT. Indeed, in mice bearing tumors larger than 150 mm
2
, metastatic lesions were observed 
in the liver and lung. Since EMT has been implicated as an essential process for metastases, it is 
plausible that CUZD1 is involved in reprogramming cancer cells toward a mesenchymal and 
potentially more invasive state, leading to invasion and metastases. Therefore, we investigated 
whether CUZD1 plays a role in EMT and if so, what the EMT-specific genes and signaling 
pathways it regulates. Here we provide evidence that overexpression of CUZD1 promotes 
activation of key signaling pathways that are critical for EMT.  
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MATERIALS AND METHODS 
Orthotopic intraductal injection of cells into mammary gland 
HC11-LacZ or HC11-Cuzd1 cells (1 × 10
6
) were suspended in Matrigel and injected into the teat 
of the fourth abdominal mammary gland of nude (nu/nu) mice as described [8] Tumor growth 
was measured by weekly caliper measurement for a period of 18 weeks. All animal experiments 
were conducted in accordance with protocols approved by University of Illinois Institutional 
Animal Care and Use Committee. After 18 weeks, the mice were euthanized by CO2. The 
primary mammary tumors, superficial lymph nodes, lung and liver were harvested from 
sacrificed animals and fixed in 4% paraformaldehyde for subsequent H&E staining or 
immunohistochemistry.  
Isolation of primary breast tumor cell lines 
Isolated tissue from late stage tumors (>20-weeks post-injection) was first placed into a cell 
culture dish containing PBS and the necrotic tumor tissue was removed. Tumor tissue was cut 
into small pieces, immediately placed in a digestion mixture of dispase (6 g/L) and collagenase 
(0.5 g/L) and incubated in 37
0
C incubator for 1 hour with agitation. The resulting mixture was 
passed through a 100 mm cell strainer and the flow-through was centrifuged at 1000 rpm for 5 
minutes. The cell pellet was washed twice in HBSS and resuspended in DMEM-F12 media with 
10% FBS, penicillin and streptavidin for 24 h. After culturing the cells for 3-4 days, they were 
replenished with RPMI-1640 along with 2.5 ug/ml of blasticidin to select for a pure population. 
This cell line was named HC11-Cuzd1Tumor 
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RNA isolation and real-time PCR analysis 
Total RNA was extracted from cultured HC11 cells using the Trizol RNA purification kit 
(Invitrogen) according to the manufacturer’s instructions. Reverse transcription was performed 
using the cDNA synthesis kit (Stratagene) following the manufacturer’s instructions. cDNA was 
amplified by quantitative real-time PCR analysis using gene-specific primers and SYBR-Green 
supermix (Bio-Rad Laboratories). 36B4 was used as the loading control. For a given sample, 
threshold cycle (Ct) and SD was calculated from individual Ct values from 3-4 replicates of a 
sample. Normalized mean Ct was computed as ΔCt by substracting mean Ct of 36B4 from Ct of 
a target gene for control sample. ΔΔCt was then calculated as a difference in ΔCt values between 
control and experimental groups. Fold change in gene expression was then computed as 2
-ΔΔCt
. 
Error bars indicates
 
2
-ΔΔCt
  ± SD. 
 
 
Histology and immunohistochemistry 
Organs were fixed by incubation in 4% paraformaldehyde overnight, paraffin embedded, and cut 
into 4- to 5-μm sections. After high-temperature antigen retrieval in citrate or EDTA buffer, 
immunohistochemistry was performed on parallel sections for overnight at 4°C, with primary 
antibodies directed against Cuzd1 (in-house), pan-Cytokeratin (Cell Signaling), vimentin 
(Sigma), twist (abcam), E-cad (Cell signaling) and slug (Cell signaling). Bound primary 
antibodies were detected with horseradish peroxidase (HRP)–conjugated goat anti-mouse or goat 
anti-rabbit secondary antibodies (Jackson Laboratiories). Sections were counterstained with 
hematoxylin and mounted.  
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Microarray and ingenuity pathway analysis 
Cells were harvested from three cell lines  HC11-LacZ, HC11-Cuzd1 or HC11-Cuzd1Tumor and 
the total RNA was isolated by Trizol reagent (Invitrogen, CA). RNA samples were processed at 
the Biotechnology Center of the University of Illinois at Urbana-Champaign. RNA integrity was 
verified using the Agilent 2100 bioanalyser. Each RNA sample was processed for microarray 
hybridization using Genechip Mouse Genome 430A 2.0 arrays (Affymetrix) following 
established protocols. The resulting data files were analyzed by Affymetrix GeneChip 
Expression Console software.  
Canonical pathways analysis identified the pathways that were most significantly enriched in the 
data set from the Ingenuity Pathways Analysis (Ingenuity Systems) (http://www.ingenuity.com/) 
a library of canonical pathways. Subsets of the related genes that were associated with a 
canonical pathway in the Ingenuity Pathways Knowledge Base were considered for further 
analysis. 
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RESULTS 
Cuzd1-driven tumors metastasize to the liver and lung 
Mice harboring CUZD1-overexpressing tumors were examined 20 weeks following tumor 
initiation for the presence of metastasis in the liver, lung and the peritoneum. Indeed, in mice 
bearing tumors larger than 150 mm
2
, surface abnormalities and visible lesions were found in the 
liver and occasionally in the lung, but not in other visceral organs. Histological examination of 
the liver and lung tissue sections confirmed invasion of mesenchymal-like breast tumor cells in 
hepatic tissue of the liver (Fig 4.1A, top panel) and alveolar tissue of the lungs (Fig 4.1B, top 
panel). These lesions were verified by pathologists as adenocarcinomas and histologically 
consistent with the primary tumor. Furthermore, these cells stained positively for CUZD1, 
confirming that CUZD1-overexpressing cells have indeed metastasized to the liver and the lung 
(Fig 4.1A and B, bottom panels).  
 
Cuzd1-overexpressing tumors undergo EMT 
EMT is considered as a prerequisite to metastasis that allows epithelial tumor cells to become 
more fibroblastic and migratory, resulting in tumor cell dissemination and formation of 
secondary tumors at distant sites. One of the earliest steps in EMT is the loss of epithelial 
markers and appearance of mesenchymal markers. To confirm whether EMT occurs in CUZD1-
overexpressing tumors, we analyzed the expression and localization of epithelial markers, such 
as cytokeratin and E-cadherin, and mesenchymal markers, such as vimentin and Slug in serial 
sections of these primary breast tumors. Although cytokeratins are abundantly expressed in 
CUZD1-overexpressing primary mammary tumors, 20-30% of the tumor cells did not stain 
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positively for pan-cytokeratin and histological analysis revealed that these cells are not epithelial 
in nature (Fig. 4.2A). These cells were also marked by downregulation of E-cadherin. We 
inferred that these cells most likely represented mesenchymal cells since they exhibited 
fibroblast-like morphology and showed strong expression of mesenchymal markers, such as 
vimentin, and Twist (Fig 4.2A).  
In order to further understand the role of CUZD1 in EMT and metastasis, we have recently 
created a cell line, HC11-Cuzd1Tumor, by enzymatically dissociating tumors (>20-weeks post-
injection) that formed in mice injected orthotopically with cells stably overexpressing CUZD1. A 
population of primary tumor cells was isolated following proper selection of the antibiotic 
resistance markers. To monitor the CUZD1-driven gene expression profiles that drive 
tumorigenesis, we utilized three cell lines: the control cell line HC11-LacZ, Cuzd1-
overexpressing cells HC11-Cuzd1 and the tumor-derived cell line HC11-Cuzd1Tumor.  Real-
time PCR analysis of EMT markers was performed on total RNA prepared from these three cell 
lines. This analysis revealed a down-regulation of the epithelial marker E-cadherin and up-
regulation of the mesenchymal marker vimentin in HC11-Cuzd1Tumor cells compared to HC11-
LacZ cells. There was also an increase in the expression of mRNAs encoding EMT-related 
transcription factors, such as Snail and Zeb2, in the HC11-Cuzd1Tumor cells, confirming our 
immunohistochemical data. The expression of other transcription factors, such as Slug and Zeb1, 
did not change in the tumor cells, indicating that CUZD1 may regulate specific signaling 
pathways acting via Snail and Zeb2 (Fig 4.2B). These data suggested that CUZD1 may drive the 
reprogramming of cancer cells toward a mesenchymal and potentially more invasive state, 
leading to metastasis. 
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Identification of Cuzd1-regulated gene networks associated with EMT  
To further examine the hypothesis that CUZD1 controls EMT during breast tumorigenesis, we 
sought to explore downstream signaling pathways associated with this transition. Our approach 
involved comparing the gene expression profiles of three HC11-based cell lines namely HC11-
LacZ, HC11-Cuzd1 and HC11-Cuzd1Tumor. The HC11-LacZ cells overexpress lacZ and serve 
as a control non-tumorigenic cell line. The HC11-Cuzd1 cells overexpress Cuzd1 and exhibit 
some tumorigenic properties, such as colony formation on soft agar and increased migration 
(described in Chapter 2). The HC11-Cuzd1Tumor cells are derived from late-stage Cuzd1-
overexpressing tumors that develop metastasic adenocarcinoma in liver and lung. We believe 
that the HC11-Cuzd1Tumor cells have undergone biological reprogramming and transformation 
from epithelial to mesenchymal-like cells in the microenvironment of the primary tumor. Total 
RNA was isolated from these three cell lines and subjected to microarray analysis. When we 
compared gene expression profiles of HC11-LacZ and HC11-Cuzd1 cells, we observed alteration 
in expression levels of many genes, which likely contributed to the tumorigenesis pathway. 
Similarly, the expression of many genes was significantly altered when gene expression profile 
of HC11-Cuzd1Tumor cells was compared to that of HC11-LacZ. These genes are likely 
involved in EMT and metastasis.   
When the results of these two microarray analyses were compared, we found that the expression 
of 250 genes was up-regulated (>1.5-fold, p-value <0.1)and that of 168 genes was down-
regulated (<1.5-fold, p-value <0.1) in both microarray analyses. The candidate up-regulated (Fig 
4.3, A and B) and down-regulated genes (Fig 4.3, C and D) were classified according to their 
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known biological functions and the canonical pathways by ingenuity pathway analysis (IPA). 
Among the genes whose expression was altered, several with known roles in tumorigenesis and 
metastasis were prominent. These genes control cellular growth and proliferation, cellular 
development, cell-cell interaction, cellular movement and invasion. Among the up-regulated 
genes were the ILK (integrin-linked kinase), Rho, TGF-β, and Wnt signaling pathways. We also 
observed downregulation of the tight junction pathway. These pathways are implicated in EMT.  
Genes identified by microarray analysis were further validated using real-time PCR 
analysis. As shown in Fig 3.4E observed a marked up-regulation of (i) molecules that belong to 
the TGFβ and Wnt signaling pathways, such as TGF-β1 and β-catenin coactivator BCL9; (ii) 
molecules that belong to the ILK pathway, such as the actin, ACTG2, and the integrin, IGTB4; 
and (iii) molecules that belong to the Rho signaling pathway, such as the guanine nucleotide 
exchange factor, NGEF. Additionally, the expression of molecules that belong to the tight 
junction pathway, such as the ECM component EFEMP2, the cadherins, desmocollin, and 
protocadherin18, and the cell adhesion molecule contactin, were significantly down-regulated. 
Up-regulation of molecules involved in invasion and downregulation of molecules involved in 
adhesion clearly showed that CUZD1 helps establish the molecular signature for EMT. Further 
analysis is required to define the gene regulatory networks and precise mechanisms that operate 
during CUZD1-induced EMT and metastasis.  
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DISCUSSION  
We have shown previously that CUZD1-overexpressing cells exhibit invasive properties as 
assessed by the in vitro migration assays These cells also expressed elevated levels of the matrix-
degrading metalloproteases, MMP2 and MMP9 ((Chapter 2), which are known to promote tumor 
cell motility, invasiveness, and EMT. Several lines of evidence suggest that EMT is involved in 
cancer progression, particularly during invasion and intravasation when tumor cells migrate to 
distant organs to form metastases [6, 9]. In this study, we show that CUZD1-overexpressing 
tumors metastasize to distant secondary sites, such as the lung and the liver. Our results showed 
that overexpression of CUZD1 leads to an elevated expression of the mesenchymal marker, 
vimentin, and downregulation of the epithelial cell adhesion marker, E-cadherin. These changes 
are well-established hallmarks of EMT and support a role for CUZD1 in the regulation of EMT.  
It is important to note that Snail, the transcriptional repressor of E-cadherin, is up-regulated in 
Cuzd1-overexpressing tumors, as assessed by real-time PCR and immunohistochemical studies, 
indicating that Cuzd1-induced down-regulation of E-cadherin is likely mediated by Snail.  In 
future experiments, we will assess the expression of EMT markers in tissues obtained from lung 
and liver adenocarcinomas to understand if similar pathways are being activated.  
The microarray analysis links CUZD1 to many critical inducers of EMT, such as TGF-, ILK, 
Rho and Wnt signaling pathways. TGF-, a well-known mediator of EMT, is highly induced in 
CUZD1-overexpressing cells. TGF-functions both as a tumor suppressor and a tumor 
promoter [10]. In fact, the TGF- pathway is known to prevent epithelial cell transformation by 
inhibiting proliferation and inducing senescence or apoptosis. On the other hand, during 
advanced tumorigenesis, enhanced TGF- signaling is associated with cancer progression via 
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increased tumor cell motility, invasiveness and ultimately metastasis. TGF- cooperates with the 
Ras and canonical Wnt/-catenin pathway to induce EMT. It was also reported that a Snail-
SMAD3/4 transcriptional repressor complex promotes TGF--mediated EMT [11]. ILK is a key 
component of focal adhesions that binds to integrins 1-3 and is indispensable for integrin 
function during development [12]. During EMT and metastasis, overexpression of ILK leads to 
nuclear translocation of -catenin, increased invasiveness and repression of E-cadherin [13] via 
upregulation of Snail expression [14, 15]. ILK is also involved in TGF--mediated EMT of 
human keratinocytes [16]. Rho family GTPases and their regulatory molecules, GEFs and GAPs, 
exert important roles in epithelial plasticity and are essential effectors of EMT induced by TGF- 
and other stimuli [17]. There is plenty of evidence from the literature, suggesting an interplay 
between the Wnt, Rho and ILK pathways and indicating TGF- as an important regulator of 
these pathways.  
CUZD1 dramatically induces the expression of TGF- and its downstream signaling molecules, 
such as the MMPs, ACTG2 and NGEF. Taken together, these data raise the possibility that 
CUZD1 regulates EMT via the TGF- pathway.  Classic TGF- signaling requires that it binds 
to the type II TGF- receptor followed by transphosphorylation of a type I receptor, and 
subsequent phosphorylation of Smad2 and Smad3. Phosphorylated Smad2/3 forms a trimer with 
Smad4, which then translocates to the nucleus and interacts with transcription machinery to 
suppress epithelial cell-specific genes and promote the expression of mesenchyme-specific 
genes. Many groups have shown that TGF- can induce EMT, but the precise signaling cascades 
involved are not completely understood. A future goal of this project is to use cell-based assays 
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and siRNA approaches to functionally address how CUZD1 regulates TGF- and its downstream 
pathways to direct EMT.  
It is also important to understand the role of EMT in later stages of the invasion-metastasis 
cascade, including intravasation, tumor-cell survival in the circulation, extravasation, and finally 
establishment/expansion of the micro-metastatic lesion in a distant target site.  For this, we have 
created HC11-LacZ and HC11-Cuzd1 cells that are tagged with ZsGreen, a brighter and more 
stable alternative to GFP for fluorescent tracking of these cells (J.Mapes and MKB, 
unpublished).  Using these cells, it should be possible to determine the time course and pattern of 
tumor growth and metastasis in vivo by tracking fluorescence through intravital microscopy.  
 
Finally, it is also important to analyze human breast cancer tissues and assess possible 
correlation between CUZD1 expression, tumor recurrence and metastasis. Understanding the 
mechanism of action of CUZD1 and other molecules in EMT and metastasis may help us 
formulate new intervention strategies to prevent tumor metastasis. Both EMT and tumor-host 
microenvironment cross-talk contribute to the progression and severity of metastasis. In the 
future, it will be important to understand the molecular signature of EMT and aberrant host-
microenvironment interactions to develop effective therapies against invasion and metastasis. 
Development of specific drugs that target and control these two broad mechanisms would 
provide powerful treatment strategies for cancer.  
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Fig 4.1. Cuzd1-overexpressing breast tumors metastasize to distant secondary sites  
A and B. The mammary glands of mice were injected with HC11-LacZ or HC11-Cuzd1 cells as 
described previously (Chapter 2). Liver (Fig A) and lung (Fig B) tissues were collected 20 weeks 
post injection, fixed, embedded in paraffin, and sectioned. Sections were subjected to H&E 
staining (top panels) or immunoflurosence or immunohistochemical analysis using an antibody 
against CUZD1 (bottom panels). 
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Fig 4.2. Cuzd1-overexpressing tumors undergo EMT 
A. Mammary glands of mice were injected with HC11-Cuzd1 cells as described previously. 
Mammary tumor tissues were collected 20 weeks post injection, fixed, and embedded in paraffin. 
Serial sections from these tissues were subjected to IHC analysis using antibodies specific for 
CUZD1, pan-cytokeratin, vimentin, E-cadherin and Snail. 
B. Total RNA was prepared from HC11-LacZ, HC11-Cuzd1 or HC11-Cuzd1Tumor cells 
and subjected to real-time PCR to analyze relative expression levels of mRNAs corresponding to 
E-Cadherin, N-Cadherin, Vimentin, Snail, Slug and Cuzd1. Data are represented as average fold 
induction ± SEM.  
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Fig 4.3. Identification of EMT and metastasis associated pathways 
A. List of common genes whose expression is up-regulated (>1.5 fold change) in HC11-
Cuzd1 cells compared to HC11-LacZ (genes implicated in tumorigenesis) and in HC11-
Cuzd1Tumor cells compared to HC11-Cuzd1 (genes implicated in EMT/Metastases). 
These pathways were categorized by biological function using Ingenuity pathway 
analysis software (IPA).  
B. List of common genes whose expression is up-regulated (>1.5 fold change) in HC11-
Cuzd1 compared to HC11-LacZ (genes implicated in tumorigenesis) and in HC11-
Cuzd1Tumor cells compared to HC11-Cuzd1 (genes implicated in EMT/Metastases). 
These pathways were categorized by canonical pathways using Ingenuity pathway 
analysis software (IPA). 
C. List of common genes whose expression is down-regulated (>-0.5 fold change) in HC11-
Cuzd1 cells compared to HC11-LacZ (genes implicated in tumorigenesis) and in HC11-
Cuzd1Tumor cells compared to HC11-Cuzd1 (genes implicated in EMT/Metastases). 
These pathways were categorized by biological function using Ingenuity pathway 
analysis software (IPA).   
D. List of common genes whose expression is down-regulated (>1.5 fold change) in HC11-
Cuzd1 compared to HC11-LacZ (genes implicated in tumorigenesis) and in HC11-
Cuzd1Tumor cells compared to HC11-Cuzd1 (genes implicated in EMT/Metastases). 
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These pathways were categorized by canonical pathways using Ingenuity pathway 
analysis software (IPA). 
E. Selected genes from the microarray analysis were verified by real-time PCR. Total RNA 
was isolated from HC11-LacZ, HC11-Cuzd1 and HC11-Cuzd1Tumor cells and subjected 
to real-time PCR to analyze relative expression levels of TGFB1, TGFB2, BCL6, 
TGFBR2, FOXC1, ACTG2, ITGB4, MYLK, NGEF, GNA13, PCDH18, CNTN. Data are 
represented as average fold induction ± SEM.  
 
 
 
 
 
